{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 130,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loaded  .. . . . . . . .\n"
     ]
    }
   ],
   "source": [
    "try:\n",
    "    import elasticsearch\n",
    "    from elasticsearch import Elasticsearch\n",
    "    \n",
    "    import pandas as pd\n",
    "    import json\n",
    "    from ast import literal_eval\n",
    "    from tqdm import tqdm\n",
    "    import datetime\n",
    "    import os\n",
    "    import sys\n",
    "    \n",
    "    import os\n",
    "    import numpy as np\n",
    "    \n",
    "    from gensim.parsing.porter import PorterStemmer\n",
    "    from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "    from sklearn.metrics.pairwise import cosine_similarity\n",
    "    \n",
    "    from elasticsearch import helpers\n",
    "    print(\"Loaded  .. . . . . . . .\")\n",
    "except Exception as E:\n",
    "    print(\"Some Modules are Missing {} \".format(E))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "read\n"
     ]
    }
   ],
   "source": [
    "df = pd.read_excel(\"elastic_Search_Data.xlsx\")\n",
    "print(\"read\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>filename</th>\n",
       "      <th>country</th>\n",
       "      <th>Product name</th>\n",
       "      <th>Refined Product Name</th>\n",
       "      <th>para_text</th>\n",
       "      <th>Possible Questions</th>\n",
       "      <th>Comment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Candesartan_PM_Reviewed.docx</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Candesartan cilexetil</td>\n",
       "      <td>Atacand (Candesartan Cilexetil)</td>\n",
       "      <td>ATACAND (candesartan cilexetil) is indicated f...</td>\n",
       "      <td>What is ATACAND used for\\nWhat is ATACAND used...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Candesartan_PM_Reviewed.docx</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Candesartan cilexetil</td>\n",
       "      <td>Atacand (Candesartan Cilexetil)</td>\n",
       "      <td>Geriatrics (&gt; 65 years of age) : No overall di...</td>\n",
       "      <td>What is the efficacy of ATACAND in elderly pop...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Candesartan_PM_Reviewed.docx</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Candesartan cilexetil</td>\n",
       "      <td>Atacand (Candesartan Cilexetil)</td>\n",
       "      <td>Pediatrics (6 to 17 years of age): \\n•\\tHypert...</td>\n",
       "      <td>What is ATACAND used for in children\\nWhat is ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Candesartan_PM_Reviewed.docx</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Candesartan cilexetil</td>\n",
       "      <td>Atacand (Candesartan Cilexetil)</td>\n",
       "      <td>ATACAND (candesartan cilexetil) is contraindic...</td>\n",
       "      <td>Who is ATACAND conracindicated in\\nWho is ATAC...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Candesartan_PM_Reviewed.docx</td>\n",
       "      <td>Canada</td>\n",
       "      <td>Candesartan cilexetil</td>\n",
       "      <td>Atacand (Candesartan Cilexetil)</td>\n",
       "      <td>There is evidence that co-administration of an...</td>\n",
       "      <td>Can ATACAND be co-administered with aliskiren\\...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                       filename country           Product name  \\\n",
       "0  Candesartan_PM_Reviewed.docx  Canada  Candesartan cilexetil   \n",
       "1  Candesartan_PM_Reviewed.docx  Canada  Candesartan cilexetil   \n",
       "2  Candesartan_PM_Reviewed.docx  Canada  Candesartan cilexetil   \n",
       "3  Candesartan_PM_Reviewed.docx  Canada  Candesartan cilexetil   \n",
       "4  Candesartan_PM_Reviewed.docx  Canada  Candesartan cilexetil   \n",
       "\n",
       "              Refined Product Name  \\\n",
       "0  Atacand (Candesartan Cilexetil)   \n",
       "1  Atacand (Candesartan Cilexetil)   \n",
       "2  Atacand (Candesartan Cilexetil)   \n",
       "3  Atacand (Candesartan Cilexetil)   \n",
       "4  Atacand (Candesartan Cilexetil)   \n",
       "\n",
       "                                           para_text  \\\n",
       "0  ATACAND (candesartan cilexetil) is indicated f...   \n",
       "1  Geriatrics (> 65 years of age) : No overall di...   \n",
       "2  Pediatrics (6 to 17 years of age): \\n•\\tHypert...   \n",
       "3  ATACAND (candesartan cilexetil) is contraindic...   \n",
       "4  There is evidence that co-administration of an...   \n",
       "\n",
       "                                  Possible Questions  Comment  \n",
       "0  What is ATACAND used for\\nWhat is ATACAND used...      NaN  \n",
       "1  What is the efficacy of ATACAND in elderly pop...      NaN  \n",
       "2  What is ATACAND used for in children\\nWhat is ...      NaN  \n",
       "3  Who is ATACAND conracindicated in\\nWho is ATAC...      NaN  \n",
       "4  Can ATACAND be co-administered with aliskiren\\...      NaN  "
      ]
     },
     "execution_count": 132,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {},
   "outputs": [],
   "source": [
    "tfidf = TfidfVectorizer()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "metadata": {},
   "outputs": [],
   "source": [
    "p = PorterStemmer()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 135,
   "metadata": {},
   "outputs": [],
   "source": [
    "answers11=list(df[\"para_text\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 300,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['ATACAND (candesartan cilexetil) is indicated for: \\n\\n•\\tHypertension\\no\\tThe treatment of mild to moderate essential hypertension.\\no\\tATACAND may be used alone or concomitantly with thiazide diuretics.\\no\\tThe safety and efficacy of concurrent use with calcium channel blockers have not been established.\\n•\\tHeart Failure\\no\\tThe treatment of NYHA Class II and III heart failure with ejection fraction\\n≤ 40% in addition to standard therapy, with or without an ACE inhibitor. ',\n",
       " 'Geriatrics (> 65 years of age) : No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. ',\n",
       " 'Pediatrics (6 to 17 years of age): \\n•\\tHypertension\\nATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see CLINICAL TRIALS).\\n•\\tHeart Failure\\nThe safety and efficacy of ATACAND in the treatment of heart failure has not been established in children and adolescents <18 years. ',\n",
       " 'ATACAND (candesartan cilexetil) is contraindicated in: \\n\\n•\\tPatients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.\\n\\n•\\tChildren aged <1 year.\\n•\\tPregnant women (see WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women).\\n\\n•\\tNursing women (see WARNINGS AND PRECAUTIONS, Special Populations, Nursing Women).\\n\\n•\\tCombination with aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR < 60 mL/min/1.73m2) (see WARNINGS and PRECAUTIONS, Dual Blockade of the Renin\\n\\n•\\t-Angiotensin System (RAS) and Renal, and DRUG INTERACTIONS, Dual Blockade of the Renin- Angiotensin-System (RAS) with ARBs, ACEIs or aliskiren-containing drugs).\\n\\n•\\tPatients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsoprtion. ',\n",
       " 'There is evidence that co-administration of angiotensin receptor antagonists (ARBs), such as ATACAND, or of angiotensin converting enzyme inhibitors (ACEIs) with aliskiren increases the risk of hypotension, syncope, stroke, hyperkalemia and deterioration of renal function, including renal failure, in patients with diabetes mellitus (type 1 or type 2) and/or moderate to severe renal impairment (GFR < 60 mL/min/1.73m2). Therefore, the use of ATACAND in combination with aliskiren-containing drugs is contraindicated in these patients (see CONTRAINDICATIONS). ',\n",
       " 'Avoid the concomitant use of ACE inhibitors and ARBs in patients with diabetic nephropathy. ',\n",
       " 'If dual blockade therapy is considered necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ',\n",
       " 'Occasionally, symptomatic hypotension has occurred after administration of candesartan cilexetil. It is more likely to occur in patients who are volume-depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting, or undergoing surgery with anaesthesia. In these patients, because of the potential fall in blood pressure (BP), therapy should be started under close medical supervision. Similar considerations apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in myocardial infarction or cerebrovascular accident. ',\n",
       " 'Heart Failure : Patients with heart failure given candesartan cilexetil commonly have some reduction in BP. Caution should be observed when initiating therapy.',\n",
       " 'Triple combination of Atacand with an ACE-inhibitor and a mineralocorticoid receptor antagonist used in heart failure is also not recommended. Use of these combinations should be under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ',\n",
       " 'Valvular Stenosis \\nThere is concern on theoretical grounds that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction. ',\n",
       " 'Heart Failure : In heart failure patients treated with ATACAND, hyperkalemia may occur. During treatment with ATACAND in patients with heart failure, periodic monitoring of serum potassium is recommended, especially when taken concomitantly with ACE inhibitors and potassium-sparing diuretics such as spironolactone. ',\n",
       " 'The effect of ATACAND on the ability to drive and use machines has not been studied, but based on its pharmacodynamic properties ATACAND is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment. ',\n",
       " ' As a consequence of inhibiting the renin-angiotensin-aldosterone system (RAAS), changes in renal function have been seen in susceptible individuals. In patients whose renal function may depend on the activity of the RAAS, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death. In susceptible patients, concomitant diuretic use may further increase risk. ',\n",
       " 'The use of ARBs, including ATACAND, or ACEIs with aliskiren-containing drugs is contraindicated in patients with moderate to severe renal impairment (GFR <60 mL/min/1.73m2) (see CONTRAINDICATIONS and DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACEIs, or aliskiren-containing drugs). ',\n",
       " 'Use of ATACAND should include appropriate assessment of renal function. ',\n",
       " 'Heart Failure : In heart failure patients, increases in serum creatinine may occur. Dosage reduction, and/or discontinuation of the diuretic, and/or ATACAND, and/or volume repletion may be required. Monitoring of serum creatinine is recommended during dose escalation and periodically thereafter. ',\n",
       " 'There is limited experience regarding the administration of ATACAND in adult patients with renal transplant. ',\n",
       " 'ATACAND is contraindicated during pregnancy (see CONTRAINDICATIONS). Drugs that act directly on the RAAS can cause fetal and neonatal morbidity and death when administered to pregnant women. When pregnancy is detected, ATACAND should be discontinued as soon as possible.',\n",
       " 'Epidemiological evidence regarding the risk of teratogenicity following exposure to ACEIs during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Given the current evidence available on the risk with ARBs, similar risks may exist for this class of drugs. Patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ARBs should be stopped immediately, and, if appropriate, alternative therapy should be started.',\n",
       " 'The use of ARBs during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). ',\n",
       " 'Animal data : Oral doses ≥ 10 mg candesartan cilexetil/kg/day administered to pregnant rats during late gestation and continued through lactation were associated with reduced survival and an increased incidence of hydronephrosis in the offspring. Candesartan cilexetil given to pregnant rabbits at an oral dose of 3 mg/kg/day caused maternal toxicity (decreased body weight and death) but, in surviving dams, had no adverse effects on fetal survival, fetal weight, or external, visceral, or skeletal development. No maternal toxicity or adverse effects on fetal development were observed when oral doses ≤1000 mg candesartan cilexetil/kg/day were administered to pregnant mice. ',\n",
       " 'it is not known whether candesartan is excreted in human milk, but significant levels have been found in the milk of lactating rats. Because many drugs are excreted in human milk, and because of their potential for adversely affecting the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. ',\n",
       " 'In utero exposure : Infants with a history of in utero exposure to ARBs should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function; however, limited experience with those procedures has not been associated with significant clinical benefit. Candesartan cilexetil is not removed from plasma by dialysis. ',\n",
       " 'Animal data-Heart development : In preclinical studies in normotensive neonatal and juvenile rats, candesartan caused a reduction in relative and absolute heart weights. As in adult animals, these effects were considered to result from the pharmacological action of candesartan. At the lowest dose of 10 mg/kg, exposure to candesartan was 7-54x those found in children aged 6 to <17 years who received 16 mg of candesartan cilexetil. Since a NOAEL (no observed adverse effect level) could not be established in these studies, the safety margin for the effects on heart weight could not be determined. The clinical relevance of this finding is unknown. ',\n",
       " 'Black pediatric patients:  The antihypertensive effect of candesartan is less pronounced in Black patients compared with non-Black patients. ',\n",
       " 'Volume-depleted patients : For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), ATACAND treatment should be initiated under close medical supervision and a lower starting dose should be considered (see DOSAGE AND ADMINISTRATION, Pediatrics).',\n",
       " 'Renal impairment : ATACAND has not been studied in children aged 6 to 17 years with renal impairment (see DOSAGE AND ADMINISTRATION, Pediatrics).',\n",
       " 'There is no experience regarding the administration of ATACAND in children aged 6 to <17 years with a renal transplant. ',\n",
       " 'Hepatic impairment : There are no data on the effects of ATACAND in pediatric patients with hepatic impairment. \\n',\n",
       " 'Type 1 diabetes : There is no experience regarding the administration of ATACAND in children aged 6 to <17 years with type 1 diabetes. ',\n",
       " 'No overall differences in safety or effectiveness were observed between subjects >65 years of age and younger subjects. In addition, other reported clinical experience has not identifieddifferences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.',\n",
       " 'Potentially serious adverse reactions reported rarely with candesartan cilexetil in controlled clinical trials were syncope and hypotension. ',\n",
       " 'The adverse reaction profile of ATACAND as a treatment for hypertension in pediatric patients appeared similar to that seen in adults. However, the frequency of all adverse events (AEs) seemed higher.',\n",
       " 'Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking ATACAND for 4 weeks and 1 year, respectively. ',\n",
       " 'Severe adverse reactions most commonly seen in adult heart failure patients taking candesartan cilexetil in controlled clinical trials were hypotension, hyperkalemia and renal impairment. ',\n",
       " 'Clinical Trial Adverse Drug Reactions \\nBecause clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug.  Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates .',\n",
       " 'ATACAND (candesartan cilexetil) was evaluated for safety in >8700 patients treated for hypertension, including 677 treated for ≥6 months and 626 for ≥1 year. Of these, 8694 were treated with candesartan cilexetil monotherapy in controlled clinical trials.',\n",
       " 'In placebo-controlled clinical trials, discontinuation due to AEs occurred in 2.9% and 2.7% of patients treated with ATACAND monotherapy and placebo, respectively.',\n",
       " 'In the double blind, placebo-controlled trials, the overall incidence of AEs showed no association with dose, age or gender. In these trials, the following AEs reported with ATACAND occurred in ≥ 1% of patients, regardless of drug relationship: ',\n",
       " 'Clinical trials in which doses ≤32 mg were administered did not result in a significant increase in any of the AEs listed above. ',\n",
       " 'ATACAND was evaluated for safety in 240 hypertensive pediatric patients aged 6 to 17 years during a 4-week placebo-controlled clinical trial and in 235 pediatric patients in the 1-year open-label extension study. A total of 213 pediatric patients from the placebo-controlled trial enrolled in the open-label study. There were 178 patients who were treated for ≥1 year.',\n",
       " 'The adverse reaction profile of ATACAND in pediatric patients appeared similar to that seen adults. However, the frequency of all AEs seemed higher.',\n",
       " 'In the placebo-controlled clinical trial, the most common AEs (≥3% of patients) were cough, dizziness, headache, pharyngolaryngeal pain and upper respiratory tract infection. Dizziness was the most common drug-related AE.',\n",
       " 'In the open-label extension study, 3 out of 240 pediatric patients aged 6 to 17 years experienced worsening renal disease. The association between candesartan and the exacerbation of the underlying condition could not be excluded',\n",
       " 'Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking ATACAND for 4 weeks and 1 year, respectively. ',\n",
       " 'The AE profile of ATACAND in adult heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. In the CHARM-Alternative and CHARM-Added studies comparing ATACAND in total daily doses ≤32 mg once daily to placebo, 23.2 % of ATACAND and 18.4% of placebo patients discontinued the treatment due to AEs.',\n",
       " 'In these trials, the following AEs reported with ATACAND occurred in ≥ 1% of patients and with higher frequency than placebo, regardless of drug relationship. ',\n",
       " 'Less Common Clinical Trial Adverse Drug Reactions (< 1%) \\n\\nHypertension ',\n",
       " 'The following AEs were reported at an incidence of < 1% in controlled clinical trials (in >1 patient, with higher frequency than placebo): \\n\\nBody as a Whole:  allergy, asthenia, pain, syncope. \\nCardiovascular:  angina pectoris, circulatory failure, flushing, hypotension, myocardial infarction, peripheral ischemia, thrombophlebitis. \\nCentral and Peripheral Nervous System:  hypertonia, hypoesthesia, paresthesia, vertigo.  \\nGastrointestinal:  constipation, dry mouth, dyspepsia, toothache .\\nHearing:  tinnitus. \\nMetabolic and Nutritional:  diabetes mellitus, hyperkalemia, hyponatremia.  \\nMusculoskeletal:  arthritis, arthropathy, myalgia, myopathy, skeletal pain, tendon disorder.  \\nBlood:  anemia, epistaxis. \\nPsychiatric:  depression, impotence, neurosis.  \\nReproductive:  menopausal symptoms. \\nResistance Mechanism:  otitis.  \\nRespiratory:  laryngitis. \\nSkin:  eczema, pruritus, rash, skin disorder, sweating, (rarely) urticaria.  \\nUrinary:  abnormal urine, cystitis. \\nVision:  conjunctivitis. ',\n",
       " 'AEs reported at a rate >1% but at about the same or greater incidence in patients receiving placebo, in studies using daily doses >16 mg: albuminuria, arthralgia, chest pain and sinusitis',\n",
       " 'Other AEs reported at an incidence of ≥0.5% from >3200 patients treated worldwide include anxiety, dyspnea, fever, gastroenteritis, hematuria, hyperglycemia, hypertriglyceridemia, hyperuricemia, increased creatinine phosphokinase, palpitation, somnolence and tachycardia. ',\n",
       " 'The following listed AEs occurred in <1% of patients treated with ATACAND but in ≥2 patients and with more frequent occurrence in the ATACAND group than in the placebo group (CHARM-Alternative and CHARM-Added). \\nSkin and Appendages Disorders:  angioedema, pruritus, rash.  \\nLiver and Biliary System Disorders:  hepatic function abnormal. \\nWhite Cell and Resistance Disorders:  granulocytopenia, leukopenia. ',\n",
       " 'Abnormal Hematologic and Clinical Chemistry Findings  Laboratory Test Findings \\nHypertension \\n\\nIn controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of ATACAND. ',\n",
       " 'Liver Function Tests:  In controlled clinical trials, elevations of AST and ALT (> 3x the upper limit of normal) occurred in 0.3% and 0.5%, respectively, of patients treated with ATACAND monotherapy compared to 0.2% and 0.4%, respectively, of patients receiving placebo. ',\n",
       " 'Serum Potassium:  A small increase (mean increase of 0.1 mEq/L) was observed in hypertensive patients treated with ATACAND alone but was rarely of clinical importance. ',\n",
       " 'Creatinine, Blood Urea Nitrogen, and Sodium:  Infrequent minor increases in blood urea nitrogen (BUN) and serum creatinine as well as decreases in sodium were observed. ',\n",
       " 'Hemoglobin and Hematocrit:  Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.2 g/dL and 0.5 volume %, respectively) were observed in patients treated with ATACAND alone but were rarely of clinical importance. Anemia, leukopenia and thrombocytopenia were associated with withdrawal of 1 patient each from clinical trials. ',\n",
       " 'Hyperuricemia:  Hyperuricemia was rarely found (0.6% of patients treated with ATACAND and 0.5% of patients treated with placebo). ',\n",
       " 'Heart Failure \\n\\nIncreases in serum creatinine, potassium and urea, and decreases in hemoglobin and hematocrit were observed. ',\n",
       " 'Post-Market Adverse Drug Reactions \\nIn post-marketing experience, the following have been reported in patients treated with ATACAND: \\n\\nBlood and lymphatic disorders:  thrombocytopenia \\n\\nCardiac disorders:  atrial fibrillation, bradycardia, cardiac failure, palpitations \\n\\nDigestive:  abnormal hepatic function and hepatitis \\n\\nGastrointestinal disorders:  pancreatitis \\n\\nGeneral disorders and administration site conditions:  chest pain, malaise, sudden death \\n\\nHematologic:  agranulocytosis, leukopenia and neutropenia \\n\\nImmunologic:  angioedema, involving swelling of the face, lips and/or tongue, hypersensitivity \\n\\nInfections and infestations:  pneumonia \\n\\nInvestigations:  blood creatinine increased, fall \\n\\nMetabolic and Nutritional Disorders:  hyperkalemia and hyponatremia  \\nMusculoskeletal System:  muscle pain, muscle weakness, myositis and rhabdomyolysis  \\nNervous system disorders:  cerebrovascular accident, loss of consciousness, presyncope  \\nPsychiatric disorders:  confusional state \\nRespiratory System Disorders:  cough, pulmonary edema \\n\\nSkin and Appendages Disorders:  pruritus, rash and urticarial \\n\\nUrogenital System:  renal impairment, including renal failure in elderly susceptible patients (see WARNINGS AND PRECAUTIONS, Renal, Renal Impairment for definition of susceptible patients) ',\n",
       " 'In vitro studies indicate that cytochrome P450 isoenzyme CYP 2C9 is involved in the biotransformation of candesartan to its inactive metabolite. Based on in vitro data, no interaction would be expected to occur in vivo with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4.\\nInteraction studies have only been performed in adults. \\n',\n",
       " 'ATACAND may be taken with or without food ',\n",
       " 'The dosage of ATACAND (candesartan cilexetil) must be individualized .',\n",
       " 'Recommended Dose and Dosage Adjustment \\n\\nATACAND should be taken once daily, at approximately the same time each day, with or without food. ',\n",
       " 'Hypertension \\n\\nAdults \\n\\nInitiation of therapy requires consideration of recent antihypertensive treatment, the extent of BP elevation, salt restriction, and other pertinent clinical factors. The dosage of other antihypertensive agents used with ATACAND may need to be adjusted. BP response is dose related over the range of 4 - 32 mg.',\n",
       " 'The recommended initial dose of ATACAND is 16 mg, once daily when used as monotherapy. Total daily doses of ATACAND should range from 8- 32 mg. Doses >32 mg do not appear to have a greater effect on BP reduction, and there is relatively little experience with such doses. Most of the antihypertensive effect is present within 2 weeks and the maximal BP reduction is generally obtained within 4 weeks. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function) consideration should be given to administration of a lower dose. If BP is not controlled by ATACAND alone, a thiazide diuretic may be added (See DRUG INTERACTIONS, Drug-Drug Interactions, Diuretics). ',\n",
       " 'Concomitant Diuretic Therapy \\nIn patients receiving diuretics, ATACAND therapy should be initiated with caution, since these patients may be volume-depleted and thus more likely to experience hypotension following initiation of additional antihypertensive therapy.',\n",
       " \"Whenever possible, all diuretics should be discontinued 2-3 days prior to the administration of ATACAND, to reduce the likelihood of hypotension (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension).  If this is not possible because of the patient's condition, ATACAND should be administered with caution and BP monitored closely. Thereafter, the dosage should be adjusted according to the individual response of the patient. \",\n",
       " 'Hepatic Impairment \\nMild to moderate hepatic impairment:  No dosage adjustment is necessary. ',\n",
       " 'Severe hepatic impairment and/or cholestasis:  There is only limited experience. In patients with severely impaired hepatic function, a lower initial dose of 4 mg should be considered. ',\n",
       " 'Renal Impairment \\nMild renal impairment:  No dosage adjustment is necessary ',\n",
       " 'Moderate or severe renal impairment or patients undergoing dialysis:  A lower initial dose of 4 mg should be considered. ',\n",
       " 'Geriatrics (> 65 years of age) \\nNo dosage adjustment is necessary for elderly patients. As greater sensitivity of some older patients cannot be ruled out, appropriate caution is recommended (see WARNINGS AND PRECAUTIONS, Geriatrics). ',\n",
       " 'Paediatrics\\n•\\tPatients weighing <50 kg:  The recommended starting dose is 4 mg once daily.\\n\\nIn some patients whose BP is not adequately controlled, the dose can be increased to 8 mg once daily.\\nThe maximum dose is 8 mg once daily ',\n",
       " '•\\tPatients weighing ≥ 50 kg:  The recommended starting dose is 8 mg once daily.\\n\\nIn some patients whose BP is not adequately controlled, the dose can be increased to 16 mg once daily.\\nThe maximum dose is 16 mg once daily.\\n\\nThe dose should be adjusted according to BP response.\\n\\nMost of the antihypertensive effect is attained within 4 weeks. ',\n",
       " 'Doses >32 mg have not been studied in pediatric patients.',\n",
       " 'For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), ATACAND treatment should be initiated under close medical supervision and a lower starting dose than the general starting dose above should be considered (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics). ',\n",
       " 'The usual recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily which is achieved by doubling the dose at approximately 2 week intervals, as tolerated by the patient. ATACAND can be administered with other heart failure treatments including ACEIs, beta-blockers, diuretics, digoxin, and/or spironolactone. ',\n",
       " 'No initial dose adjustment is necessary for elderly patients or in patients with renal or hepatic impairment. ',\n",
       " 'The safety and efficacy of ATACAND in the treatment of heart failure have not been established in children and adolescents <18 years of age. ',\n",
       " 'If a patient misses a dose of ATACAND and remembers within 12 hours, the patient should take the dose as soon as possible and then go back to the regular schedule. If it is more than 12 hours after the patient remembers, they should not take the missed dose; the next dose should be taken on time.',\n",
       " 'A double dose of ATACAND should never be taken to make up for a missed dose. ',\n",
       " 'Limited data are available in regard to overdosage in humans. The most likely manifestations of overdosage would be hypotension, dizziness and tachycardia; bradycardia could occur from reflex parasympathetic (vagal) stimulation. In case reports detailing overdosage [≤672 mg ATACAND (candesartan cilexetil)] in adults, patient recovery was uneventful.',\n",
       " 'If symptomatic hypotension should occur, supportive treatment should be instituted and vital signs monitored. The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be increased by infusion of, for example, isotonic saline solution. Sympathomimetic drugs may also be administered if the above-mentioned measures are not sufficient. Candesartan cilexetil is not removed from the plasma by hemodialysis. ',\n",
       " 'ATACAND (candesartan cilexetil) antagonizes angiotensin II by blocking the angiotensin type one (AT1) receptor. Angiotensin II is the primary vasoactive hormone of RAAS with effects that include vasoconstriction, stimulation of aldosterone secretion and renal reabsorption of sodium.',\n",
       " 'Candesartan cilexetil, a prodrug, is rapidly converted to the active drug, candesartan, during absorption from the gastrointestinal tract.',\n",
       " 'Candesartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis. There is also an AT2 receptor found in many tissues, but it plays no known role in cardiovascular homeostasis to date. Candesartan has a much greater affinity (> 10,000 fold) for the AT1 receptor than for the AT2 receptor. The strong bond between candesartan and the AT1 receptor is a result of tight binding to and slow dissociation from the receptor.',\n",
       " 'Candesartan does not inhibit ACE, also known as kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin, nor does it bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. ',\n",
       " 'Candesartan inhibits the pressor effects of angiotensin II infusion in a dose dependent manner. After 1 week of once-daily dosing of 8 mg candesartan cilexetil, the pressor effect was inhibited by approximately 90% at peak (4-8 hours after dosing) with approximately 50% inhibition persisting at 24 hours.',\n",
       " 'Plasma concentrations of angiotensin I, angiotensin II, and plasma renin activity, increased in a dose-dependent manner after single and repeated administration of candesartan cilexetil to adult healthy subjects, hypertensive and heart failure patients. A decrease in the plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was administered to hypertensive patients. ',\n",
       " 'Absorption : Following oral administration of candesartan cilexetil as a tablet, the absolute bioavailability of candesartan is estimated to be approximately 15%. After tablet ingestion, the peak serum concentration (Cmax) is reached after 3-4 hours. Food does not affect the bioavailability of candesartan after candesartan cilexetil administration .',\n",
       " 'Distribution:  The volume of distribution of candesartan is 0.13 L/kg. Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells. The protein binding is constant at candesartan plasma concentrations well above the range achieved with recommended doses. In rats, it has been demonstrated that candesartan does cross the blood- brain barrier. It has also been demonstrated in rats that candesartan passes across the placental barrier and is distributed in the fetus .',\n",
       " 'Metabolism : Candesartan cilexetil is rapidly and completely bioactivated to candesartan by ester hydrolysis during absorption from the gastrointestinal tract. It undergoes minor hepatic metabolism by O-deethylation to an inactive metabolite. In vitro studies indicate that cytochrome P450 isoenzyme CYP 2C9 is involved in the biotransformation of candesartan to its inactive metabolite. Based on in vitro data, no interaction would be expected to occur in vivo with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4. ',\n",
       " 'Excretion : Total plasma clearance of candesartan is 0.37 mL/min/kg, with a renal clearance of 0.19 mL/min/kg. Candesartan is mainly excreted unchanged in urine and feces (via bile). When candesartan cilexetil is administered orally, about 26% of the dose is excreted as candesartan in urine. Following an oral dose of 14C-labeled candesartan cilexetil, approximately 33% of radioactivity is recovered in urine and approximately 67% in feces. Following an intravenous (iv) dose of 14C-labeled candesartan, approximately 59% of radioactivity is recovered in urine and approximately 36% in feces. Biliary excretion contributes to the elimination of candesartan. The elimination half-life of candesartan is approximately 9 hours. After single and repeated administration, the pharmacokinetics of candesartan are linear for oral doses ≤32 mg. Candesartan and its inactive metabolite do not accumulate in serum upon repeated once-daily dosing. ',\n",
       " 'Geriatrics : The plasma concentration of candesartan was higher in the elderly (≥ 65 years old) (Cmax was approximately 50% higher, and AUC was approximately 80% higher) compared to younger subjects administered the same dose. The pharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite did not accumulate in the serum of these subjects upon repeated, once-daily administration. ',\n",
       " 'Pediatrics (6 to 17 years of age) : Pediatric (6 to 17 years of age) hypertensive patients that received a 16 mg dose of candesartan cilexetil had exposure similar to adults given the same dose. The pharmacokinetics (Cmax and AUC) were not modified by age, sex or body weight. From the dose-ranging studies of candesartan cilexetil, there was a dose related increase in plasma candesartan concentrations.',\n",
       " 'ATACAND pharmacokinetics have not been determined in children and adolescent (6 to 17 years of age) with renal insufficiency. ',\n",
       " 'Gender : No gender-related differences in the pharmacokinetics of candesartan have been observed.']"
      ]
     },
     "execution_count": 300,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "answers11"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 221,
   "metadata": {},
   "outputs": [],
   "source": [
    "answers=p.stem_documents(answers11)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 222,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['atacand (candesartan cilexetil) is indic for: • hypertens o the treatment of mild to moder essenti hypertension. o atacand mai be us alon or concomitantli with thiazid diuretics. o the safeti and efficaci of concurr us with calcium channel blocker have not been established. • heart failur o the treatment of nyha class ii and iii heart failur with eject fraction ≤ 40% in addit to standard therapy, with or without an ac inhibitor.',\n",
       " 'geriatr (> 65 year of age) : no overal differ in safeti or effect were observ between these subject and younger subjects, and other report clinic experi ha not identifi differ in respons between the elderli and younger patients, but greater sensit of some older individu cannot be rule out.',\n",
       " 'pediatr (6 to 17 year of age): • hypertens atacand is indic for the treatment of essenti hypertens in children and adolesc 6 to 17 year of ag (see clinic trials). • heart failur the safeti and efficaci of atacand in the treatment of heart failur ha not been establish in children and adolesc <18 years.',\n",
       " 'atacand (candesartan cilexetil) is contraind in: • patient who ar hypersensit to thi drug or to ani ingredi in the formul or compon of the container. for a complet listing, see dosag forms, composit and packag section of the product monograph. • children ag <1 year. • pregnant women (see warn and precautions, special populations, pregnant women). • nurs women (see warn and precautions, special populations, nurs women). • combin with aliskiren-contain drug in patient with diabet mellitu (type 1 or type 2) or moder to sever renal impair (gfr < 60 ml/min/1.73m2) (see warn and precautions, dual blockad of the renin • -angiotensin system (ras) and renal, and drug interactions, dual blockad of the renin- angiotensin-system (ras) with arbs, acei or aliskiren-contain drugs). • patient with rare hereditari problem of galactos intolerance, the lapp lactas defici or glucose-galactos malabsoprtion.',\n",
       " 'there is evid that co-administr of angiotensin receptor antagonist (arbs), such as atacand, or of angiotensin convert enzym inhibitor (aceis) with aliskiren increas the risk of hypotension, syncope, stroke, hyperkalemia and deterior of renal function, includ renal failure, in patient with diabet mellitu (type 1 or type 2) and/or moder to sever renal impair (gfr < 60 ml/min/1.73m2). therefore, the us of atacand in combin with aliskiren-contain drug is contraind in these patient (see contraindications).',\n",
       " 'avoid the concomit us of ac inhibitor and arb in patient with diabet nephropathy.',\n",
       " 'if dual blockad therapi is consid necessary, thi should onli occur under specialist supervis and subject to frequent close monitor of renal function, electrolyt and blood pressure.',\n",
       " 'occasionally, symptomat hypotens ha occur after administr of candesartan cilexetil. it is more like to occur in patient who ar volume-deplet by diuret therapy, dietari salt restriction, dialysis, diarrhea or vomiting, or undergo surgeri with anaesthesia. in these patients, becaus of the potenti fall in blood pressur (bp), therapi should be start under close medic supervision. similar consider appli to patient with ischem heart or cerebrovascular disease, in whom an excess fall in blood pressur could result in myocardi infarct or cerebrovascular accident.',\n",
       " 'heart failur : patient with heart failur given candesartan cilexetil commonli have some reduct in bp. caution should be observ when initi therapy.',\n",
       " 'tripl combin of atacand with an ace-inhibitor and a mineralocorticoid receptor antagonist us in heart failur is also not recommended. us of these combin should be under specialist supervis and subject to frequent close monitor of renal function, electrolyt and blood pressure.',\n",
       " 'valvular stenosi there is concern on theoret ground that patient with aortic stenosi might be at particular risk of decreas coronari perfus when treat with vasodil becaus thei do not develop as much afterload reduction.',\n",
       " 'heart failur : in heart failur patient treat with atacand, hyperkalemia mai occur. dure treatment with atacand in patient with heart failure, period monitor of serum potassium is recommended, especi when taken concomitantli with ac inhibitor and potassium-spar diuret such as spironolactone.',\n",
       " 'the effect of atacand on the abil to drive and us machin ha not been studied, but base on it pharmacodynam properti atacand is unlik to affect thi ability. when drive vehicl or oper machines, it should be taken into account that dizzi or weari mai occur dure treatment.',\n",
       " 'as a consequ of inhibit the renin-angiotensin-aldosteron system (raas), chang in renal function have been seen in suscept individuals. in patient whose renal function mai depend on the activ of the raas, such as patient with bilater renal arteri stenosis, unilater renal arteri stenosi to a solitari kidney, or sever congest heart failure, treatment with agent that inhibit thi system ha been associ with oliguria, progress azotemia, and rarely, acut renal failur and/or death. in suscept patients, concomit diuret us mai further increas risk.',\n",
       " 'the us of arbs, includ atacand, or acei with aliskiren-contain drug is contraind in patient with moder to sever renal impair (gfr <60 ml/min/1.73m2) (see contraind and drug interactions, dual blockad of the renin-angiotensin-system (ras) with arbs, aceis, or aliskiren-contain drugs).',\n",
       " 'us of atacand should includ appropri assess of renal function.',\n",
       " 'heart failur : in heart failur patients, increas in serum creatinin mai occur. dosag reduction, and/or discontinu of the diuretic, and/or atacand, and/or volum replet mai be required. monitor of serum creatinin is recommend dure dose escal and period thereafter.',\n",
       " 'there is limit experi regard the administr of atacand in adult patient with renal transplant.',\n",
       " 'atacand is contraind dure pregnanc (see contraindications). drug that act directli on the raa can caus fetal and neonat morbid and death when administ to pregnant women. when pregnanc is detected, atacand should be discontinu as soon as possible.',\n",
       " 'epidemiolog evid regard the risk of teratogen follow exposur to acei dure the first trimest of pregnanc ha not been conclusive; howev a small increas in risk cannot be excluded. given the current evid avail on the risk with arbs, similar risk mai exist for thi class of drugs. patient plan pregnanc should be chang to altern anti-hypertens treatment which have an establish safeti profil for us in pregnancy. when pregnanc is diagnosed, treatment with arb should be stop immediately, and, if appropriate, altern therapi should be started.',\n",
       " 'the us of arb dure the second and third trimest is known to induc human fetotox (decreas renal function, oligohydramnios, skull ossif retardation) and neonat toxic (renal failure, hypotension, hyperkalaemia).',\n",
       " 'anim data : oral dose ≥ 10 mg candesartan cilexetil/kg/dai administ to pregnant rat dure late gestat and continu through lactat were associ with reduc surviv and an increas incid of hydronephrosi in the offspring. candesartan cilexetil given to pregnant rabbit at an oral dose of 3 mg/kg/dai caus matern toxic (decreas bodi weight and death) but, in surviv dams, had no advers effect on fetal survival, fetal weight, or external, visceral, or skelet development. no matern toxic or advers effect on fetal develop were observ when oral dose ≤1000 mg candesartan cilexetil/kg/dai were administ to pregnant mice.',\n",
       " 'it is not known whether candesartan is excret in human milk, but signific level have been found in the milk of lactat rats. becaus mani drug ar excret in human milk, and becaus of their potenti for advers affect the nurs infant, a decis should be made whether to discontinu nurs or to discontinu the drug, take into account the import of the drug to the mother.',\n",
       " 'in utero exposur : infant with a histori of in utero exposur to arb should be close observ for hypotension, oliguria, and hyperkalemia. if oliguria occurs, attent should be direct toward support of blood pressur and renal perfusion. exchang transfus or dialysi mai be requir as a mean of revers hypotens and/or substitut for impair renal function; however, limit experi with those procedur ha not been associ with signific clinic benefit. candesartan cilexetil is not remov from plasma by dialysis.',\n",
       " 'anim data-heart develop : in preclin studi in normotens neonat and juvenil rats, candesartan caus a reduct in rel and absolut heart weights. as in adult animals, these effect were consid to result from the pharmacolog action of candesartan. at the lowest dose of 10 mg/kg, exposur to candesartan wa 7-54x those found in children ag 6 to <17 year who receiv 16 mg of candesartan cilexetil. sinc a noael (no observ advers effect level) could not be establish in these studies, the safeti margin for the effect on heart weight could not be determined. the clinic relev of thi find is unknown.',\n",
       " 'black pediatr patients: the antihypertens effect of candesartan is less pronounc in black patient compar with non-black patients.',\n",
       " 'volume-deplet patient : for children with possibl intravascular volum deplet (e.g. patient treat with diuretics, particularli those with impair renal function), atacand treatment should be initi under close medic supervis and a lower start dose should be consid (see dosag and administration, pediatrics).',\n",
       " 'renal impair : atacand ha not been studi in children ag 6 to 17 year with renal impair (see dosag and administration, pediatrics).',\n",
       " 'there is no experi regard the administr of atacand in children ag 6 to <17 year with a renal transplant.',\n",
       " 'hepat impair : there ar no data on the effect of atacand in pediatr patient with hepat impairment.',\n",
       " 'type 1 diabet : there is no experi regard the administr of atacand in children ag 6 to <17 year with type 1 diabetes.',\n",
       " 'no overal differ in safeti or effect were observ between subject >65 year of ag and younger subjects. in addition, other report clinic experi ha not identifieddiffer in respons between the elderli and younger patients, but greater sensit of some older individu cannot be rule out.',\n",
       " 'potenti seriou advers reaction report rare with candesartan cilexetil in control clinic trial were syncop and hypotension.',\n",
       " 'the advers reaction profil of atacand as a treatment for hypertens in pediatr patient appear similar to that seen in adults. however, the frequenc of all advers event (aes) seem higher.',\n",
       " 'sinu arrhythmia, which wa not report in adults, wa observ in 2.9% and 2.0% of pediatr patient take atacand for 4 week and 1 year, respectively.',\n",
       " 'sever advers reaction most commonli seen in adult heart failur patient take candesartan cilexetil in control clinic trial were hypotension, hyperkalemia and renal impairment.',\n",
       " 'clinic trial advers drug reaction becaus clinic trial ar conduct under veri specif condit the advers reaction rate observ in the clinic trial mai not reflect the rate observ in practic and should not be compar to the rate in the clinic trial of anoth drug. advers drug reaction inform from clinic trial is us for identifi drug-rel advers event and for approxim rate .',\n",
       " 'atacand (candesartan cilexetil) wa evalu for safeti in >8700 patient treat for hypertension, includ 677 treat for ≥6 month and 626 for ≥1 year. of these, 8694 were treat with candesartan cilexetil monotherapi in control clinic trials.',\n",
       " 'in placebo-control clinic trials, discontinu due to ae occur in 2.9% and 2.7% of patient treat with atacand monotherapi and placebo, respectively.',\n",
       " 'in the doubl blind, placebo-control trials, the overal incid of ae show no associ with dose, ag or gender. in these trials, the follow ae report with atacand occur in ≥ 1% of patients, regardless of drug relationship:',\n",
       " 'clinic trial in which dose ≤32 mg were administ did not result in a signific increas in ani of the ae list above.',\n",
       " 'atacand wa evalu for safeti in 240 hypertens pediatr patient ag 6 to 17 year dure a 4-week placebo-control clinic trial and in 235 pediatr patient in the 1-year open-label extens study. a total of 213 pediatr patient from the placebo-control trial enrol in the open-label study. there were 178 patient who were treat for ≥1 year.',\n",
       " 'the advers reaction profil of atacand in pediatr patient appear similar to that seen adults. however, the frequenc of all ae seem higher.',\n",
       " 'in the placebo-control clinic trial, the most common ae (≥3% of patients) were cough, dizziness, headache, pharyngolaryng pain and upper respiratori tract infection. dizzi wa the most common drug-rel ae.',\n",
       " 'in the open-label extens study, 3 out of 240 pediatr patient ag 6 to 17 year experienc worsen renal disease. the associ between candesartan and the exacerb of the underli condit could not be exclud',\n",
       " 'sinu arrhythmia, which wa not report in adults, wa observ in 2.9% and 2.0% of pediatr patient take atacand for 4 week and 1 year, respectively.',\n",
       " 'the ae profil of atacand in adult heart failur patient wa consist with the pharmacolog of the drug and the health statu of the patients. in the charm-altern and charm-ad studi compar atacand in total daili dose ≤32 mg onc daili to placebo, 23.2 % of atacand and 18.4% of placebo patient discontinu the treatment due to aes.',\n",
       " 'in these trials, the follow ae report with atacand occur in ≥ 1% of patient and with higher frequenc than placebo, regardless of drug relationship.',\n",
       " 'less common clinic trial advers drug reaction (< 1%) hypertens',\n",
       " 'the follow ae were report at an incid of < 1% in control clinic trial (in >1 patient, with higher frequenc than placebo): bodi as a whole: allergy, asthenia, pain, syncope. cardiovascular: angina pectoris, circulatori failure, flushing, hypotension, myocardi infarction, peripher ischemia, thrombophlebitis. central and peripher nervou system: hypertonia, hypoesthesia, paresthesia, vertigo. gastrointestinal: constipation, dry mouth, dyspepsia, toothach . hearing: tinnitus. metabol and nutritional: diabet mellitus, hyperkalemia, hyponatremia. musculoskeletal: arthritis, arthropathy, myalgia, myopathy, skelet pain, tendon disorder. blood: anemia, epistaxis. psychiatric: depression, impotence, neurosis. reproductive: menopaus symptoms. resist mechanism: otitis. respiratory: laryngitis. skin: eczema, pruritus, rash, skin disorder, sweating, (rarely) urticaria. urinary: abnorm urine, cystitis. vision: conjunctivitis.',\n",
       " 'ae report at a rate >1% but at about the same or greater incid in patient receiv placebo, in studi us daili dose >16 mg: albuminuria, arthralgia, chest pain and sinus',\n",
       " 'other ae report at an incid of ≥0.5% from >3200 patient treat worldwid includ anxiety, dyspnea, fever, gastroenteritis, hematuria, hyperglycemia, hypertriglyceridemia, hyperuricemia, increas creatinin phosphokinase, palpitation, somnol and tachycardia.',\n",
       " 'the follow list ae occur in <1% of patient treat with atacand but in ≥2 patient and with more frequent occurr in the atacand group than in the placebo group (charm-altern and charm-added). skin and appendag disorders: angioedema, pruritus, rash. liver and biliari system disorders: hepat function abnormal. white cell and resist disorders: granulocytopenia, leukopenia.',\n",
       " 'abnorm hematolog and clinic chemistri find laboratori test find hypertens in control clinic trials, clinic import chang in standard laboratori paramet were rare associ with administr of atacand.',\n",
       " 'liver function tests: in control clinic trials, elev of ast and alt (> 3x the upper limit of normal) occur in 0.3% and 0.5%, respectively, of patient treat with atacand monotherapi compar to 0.2% and 0.4%, respectively, of patient receiv placebo.',\n",
       " 'serum potassium: a small increas (mean increas of 0.1 meq/l) wa observ in hypertens patient treat with atacand alon but wa rare of clinic importance.',\n",
       " 'creatinine, blood urea nitrogen, and sodium: infrequ minor increas in blood urea nitrogen (bun) and serum creatinin as well as decreas in sodium were observed.',\n",
       " 'hemoglobin and hematocrit: small decreas in hemoglobin and hematocrit (mean decreas of approxim 0.2 g/dl and 0.5 volum %, respectively) were observ in patient treat with atacand alon but were rare of clinic importance. anemia, leukopenia and thrombocytopenia were associ with withdraw of 1 patient each from clinic trials.',\n",
       " 'hyperuricemia: hyperuricemia wa rare found (0.6% of patient treat with atacand and 0.5% of patient treat with placebo).',\n",
       " 'heart failur increas in serum creatinine, potassium and urea, and decreas in hemoglobin and hematocrit were observed.',\n",
       " 'post-market advers drug reaction in post-market experience, the follow have been report in patient treat with atacand: blood and lymphat disorders: thrombocytopenia cardiac disorders: atrial fibrillation, bradycardia, cardiac failure, palpit digestive: abnorm hepat function and hepat gastrointestin disorders: pancreat gener disord and administr site conditions: chest pain, malaise, sudden death hematologic: agranulocytosis, leukopenia and neutropenia immunologic: angioedema, involv swell of the face, lip and/or tongue, hypersensit infect and infestations: pneumonia investigations: blood creatinin increased, fall metabol and nutrit disorders: hyperkalemia and hyponatremia musculoskelet system: muscl pain, muscl weakness, myositi and rhabdomyolysi nervou system disorders: cerebrovascular accident, loss of consciousness, presyncop psychiatr disorders: confusion state respiratori system disorders: cough, pulmonari edema skin and appendag disorders: pruritus, rash and urticari urogenit system: renal impairment, includ renal failur in elderli suscept patient (see warn and precautions, renal, renal impair for definit of suscept patients)',\n",
       " 'in vitro studi indic that cytochrom p450 isoenzym cyp 2c9 is involv in the biotransform of candesartan to it inact metabolite. base on in vitro data, no interact would be expect to occur in vivo with drug whose metabol is depend upon cytochrom p450 isoenzym cyp1a2, cyp2a6, cyp2c9, cyp2c19, cyp2d6, cyp2e1 or cyp3a4. interact studi have onli been perform in adults.',\n",
       " 'atacand mai be taken with or without food',\n",
       " 'the dosag of atacand (candesartan cilexetil) must be individu .',\n",
       " 'recommend dose and dosag adjust atacand should be taken onc daily, at approxim the same time each day, with or without food.',\n",
       " 'hypertens adult initi of therapi requir consider of recent antihypertens treatment, the extent of bp elevation, salt restriction, and other pertin clinic factors. the dosag of other antihypertens agent us with atacand mai need to be adjusted. bp respons is dose relat over the rang of 4 - 32 mg.',\n",
       " 'the recommend initi dose of atacand is 16 mg, onc daili when us as monotherapy. total daili dose of atacand should rang from 8- 32 mg. dose >32 mg do not appear to have a greater effect on bp reduction, and there is rel littl experi with such doses. most of the antihypertens effect is present within 2 week and the maxim bp reduct is gener obtain within 4 weeks. for patient with possibl deplet of intravascular volum (e.g. patient treat with diuretics, particularli those with impair renal function) consider should be given to administr of a lower dose. if bp is not control by atacand alone, a thiazid diuret mai be ad (see drug interactions, drug-drug interactions, diuretics).',\n",
       " 'concomit diuret therapi in patient receiv diuretics, atacand therapi should be initi with caution, sinc these patient mai be volume-deplet and thu more like to experi hypotens follow initi of addit antihypertens therapy.',\n",
       " \"whenev possible, all diuret should be discontinu 2-3 dai prior to the administr of atacand, to reduc the likelihood of hypotens (see warn and precautions, cardiovascular, hypotension). if thi is not possibl becaus of the patient' condition, atacand should be administ with caution and bp monitor closely. thereafter, the dosag should be adjust accord to the individu respons of the patient.\",\n",
       " 'hepat impair mild to moder hepat impairment: no dosag adjust is necessary.',\n",
       " 'sever hepat impair and/or cholestasis: there is onli limit experience. in patient with sever impair hepat function, a lower initi dose of 4 mg should be considered.',\n",
       " 'renal impair mild renal impairment: no dosag adjust is necessari',\n",
       " 'moder or sever renal impair or patient undergo dialysis: a lower initi dose of 4 mg should be considered.',\n",
       " 'geriatr (> 65 year of age) no dosag adjust is necessari for elderli patients. as greater sensit of some older patient cannot be rule out, appropri caution is recommend (see warn and precautions, geriatrics).',\n",
       " 'paediatr • patient weigh <50 kg: the recommend start dose is 4 mg onc daily. in some patient whose bp is not adequ controlled, the dose can be increas to 8 mg onc daily. the maximum dose is 8 mg onc daili',\n",
       " '• patient weigh ≥ 50 kg: the recommend start dose is 8 mg onc daily. in some patient whose bp is not adequ controlled, the dose can be increas to 16 mg onc daily. the maximum dose is 16 mg onc daily. the dose should be adjust accord to bp response. most of the antihypertens effect is attain within 4 weeks.',\n",
       " 'dose >32 mg have not been studi in pediatr patients.',\n",
       " 'for children with possibl intravascular volum deplet (e.g. patient treat with diuretics, particularli those with impair renal function), atacand treatment should be initi under close medic supervis and a lower start dose than the gener start dose abov should be consid (see warn and precautions, special populations, pediatrics).',\n",
       " 'the usual recommend initi dose for treat heart failur is 4 mg onc daily. the target dose is 32 mg onc daili which is achiev by doubl the dose at approxim 2 week intervals, as toler by the patient. atacand can be administ with other heart failur treatment includ aceis, beta-blockers, diuretics, digoxin, and/or spironolactone.',\n",
       " 'no initi dose adjust is necessari for elderli patient or in patient with renal or hepat impairment.',\n",
       " 'the safeti and efficaci of atacand in the treatment of heart failur have not been establish in children and adolesc <18 year of age.',\n",
       " 'if a patient miss a dose of atacand and rememb within 12 hours, the patient should take the dose as soon as possibl and then go back to the regular schedule. if it is more than 12 hour after the patient remembers, thei should not take the miss dose; the next dose should be taken on time.',\n",
       " 'a doubl dose of atacand should never be taken to make up for a miss dose.',\n",
       " 'limit data ar avail in regard to overdosag in humans. the most like manifest of overdosag would be hypotension, dizzi and tachycardia; bradycardia could occur from reflex parasympathet (vagal) stimulation. in case report detail overdosag [≤672 mg atacand (candesartan cilexetil)] in adults, patient recoveri wa uneventful.',\n",
       " 'if symptomat hypotens should occur, support treatment should be institut and vital sign monitored. the patient should be place supin with the leg elevated. if thi is not sufficient, plasma volum should be increas by infus of, for example, isoton salin solution. sympathomimet drug mai also be administ if the above-ment measur ar not sufficient. candesartan cilexetil is not remov from the plasma by hemodialysis.',\n",
       " 'atacand (candesartan cilexetil) antagon angiotensin ii by block the angiotensin type on (at1) receptor. angiotensin ii is the primari vasoact hormon of raa with effect that includ vasoconstriction, stimul of aldosteron secret and renal reabsorpt of sodium.',\n",
       " 'candesartan cilexetil, a prodrug, is rapidli convert to the activ drug, candesartan, dure absorpt from the gastrointestin tract.',\n",
       " 'candesartan block the vasoconstrictor and aldosteron secret effect of angiotensin ii by select block the bind of angiotensin ii to the at1 receptor in mani tissues, such as vascular smooth muscl and the adren gland. it action is therefor independ of the pathwai for angiotensin ii synthesis. there is also an at2 receptor found in mani tissues, but it plai no known role in cardiovascular homeostasi to date. candesartan ha a much greater affin (> 10,000 fold) for the at1 receptor than for the at2 receptor. the strong bond between candesartan and the at1 receptor is a result of tight bind to and slow dissoci from the receptor.',\n",
       " 'candesartan doe not inhibit ace, also known as kininas ii, the enzym that convert angiotensin i to angiotensin ii and degrad bradykinin, nor doe it bind to or block other hormon receptor or ion channel known to be import in cardiovascular regulation.',\n",
       " 'candesartan inhibit the pressor effect of angiotensin ii infus in a dose depend manner. after 1 week of once-daili dose of 8 mg candesartan cilexetil, the pressor effect wa inhibit by approxim 90% at peak (4-8 hour after dosing) with approxim 50% inhibit persist at 24 hours.',\n",
       " 'plasma concentr of angiotensin i, angiotensin ii, and plasma renin activity, increas in a dose-depend manner after singl and repeat administr of candesartan cilexetil to adult healthi subjects, hypertens and heart failur patients. a decreas in the plasma concentr of aldosteron wa observ when 32 mg of candesartan cilexetil wa administ to hypertens patients.',\n",
       " 'absorpt : follow oral administr of candesartan cilexetil as a tablet, the absolut bioavail of candesartan is estim to be approxim 15%. after tablet ingestion, the peak serum concentr (cmax) is reach after 3-4 hours. food doe not affect the bioavail of candesartan after candesartan cilexetil administr .',\n",
       " 'distribution: the volum of distribut of candesartan is 0.13 l/kg. candesartan is highli bound to plasma protein (>99%) and doe not penetr red blood cells. the protein bind is constant at candesartan plasma concentr well abov the rang achiev with recommend doses. in rats, it ha been demonstr that candesartan doe cross the blood- brain barrier. it ha also been demonstr in rat that candesartan pass across the placent barrier and is distribut in the fetu .',\n",
       " 'metabol : candesartan cilexetil is rapidli and complet bioactiv to candesartan by ester hydrolysi dure absorpt from the gastrointestin tract. it undergo minor hepat metabol by o-deethyl to an inact metabolite. in vitro studi indic that cytochrom p450 isoenzym cyp 2c9 is involv in the biotransform of candesartan to it inact metabolite. base on in vitro data, no interact would be expect to occur in vivo with drug whose metabol is depend upon cytochrom p450 isoenzym cyp1a2, cyp2a6, cyp2c9, cyp2c19, cyp2d6, cyp2e1 or cyp3a4.',\n",
       " 'excret : total plasma clearanc of candesartan is 0.37 ml/min/kg, with a renal clearanc of 0.19 ml/min/kg. candesartan is mainli excret unchang in urin and fece (via bile). when candesartan cilexetil is administ orally, about 26% of the dose is excret as candesartan in urine. follow an oral dose of 14c-label candesartan cilexetil, approxim 33% of radioact is recov in urin and approxim 67% in feces. follow an intraven (iv) dose of 14c-label candesartan, approxim 59% of radioact is recov in urin and approxim 36% in feces. biliari excret contribut to the elimin of candesartan. the elimin half-lif of candesartan is approxim 9 hours. after singl and repeat administration, the pharmacokinet of candesartan ar linear for oral dose ≤32 mg. candesartan and it inact metabolit do not accumul in serum upon repeat once-daili dosing.',\n",
       " 'geriatr : the plasma concentr of candesartan wa higher in the elderli (≥ 65 year old) (cmax wa approxim 50% higher, and auc wa approxim 80% higher) compar to younger subject administ the same dose. the pharmacokinet of candesartan were linear in the elderly, and candesartan and it inact metabolit did not accumul in the serum of these subject upon repeated, once-daili administration.',\n",
       " 'pediatr (6 to 17 year of age) : pediatr (6 to 17 year of age) hypertens patient that receiv a 16 mg dose of candesartan cilexetil had exposur similar to adult given the same dose. the pharmacokinet (cmax and auc) were not modifi by age, sex or bodi weight. from the dose-rang studi of candesartan cilexetil, there wa a dose relat increas in plasma candesartan concentrations.',\n",
       " 'atacand pharmacokinet have not been determin in children and adolesc (6 to 17 year of age) with renal insufficiency.',\n",
       " 'gender : no gender-rel differ in the pharmacokinet of candesartan have been observed.']"
      ]
     },
     "execution_count": 222,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "answers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 223,
   "metadata": {},
   "outputs": [],
   "source": [
    "ml_vec= tfidf.fit_transform(answers).toarray()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 224,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[0.        , 0.        , 0.        , ..., 0.        , 0.        ,\n",
       "        0.        ],\n",
       "       [0.        , 0.        , 0.        , ..., 0.10373278, 0.        ,\n",
       "        0.32895898],\n",
       "       [0.        , 0.        , 0.        , ..., 0.20894465, 0.19286821,\n",
       "        0.        ],\n",
       "       ...,\n",
       "       [0.        , 0.        , 0.        , ..., 0.17833874, 0.        ,\n",
       "        0.        ],\n",
       "       [0.        , 0.        , 0.        , ..., 0.20835406, 0.        ,\n",
       "        0.        ],\n",
       "       [0.        , 0.        , 0.        , ..., 0.        , 0.        ,\n",
       "        0.        ]])"
      ]
     },
     "execution_count": 224,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ml_vec"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 225,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['000',\n",
       " '10',\n",
       " '1000',\n",
       " '12',\n",
       " '13',\n",
       " '14c',\n",
       " '15',\n",
       " '16',\n",
       " '17',\n",
       " '178',\n",
       " '18',\n",
       " '19',\n",
       " '213',\n",
       " '23',\n",
       " '235',\n",
       " '24',\n",
       " '240',\n",
       " '26',\n",
       " '2c9',\n",
       " '32',\n",
       " '3200',\n",
       " '33',\n",
       " '36',\n",
       " '37',\n",
       " '3x',\n",
       " '40',\n",
       " '50',\n",
       " '54x',\n",
       " '59',\n",
       " '60',\n",
       " '626',\n",
       " '65',\n",
       " '67',\n",
       " '672',\n",
       " '677',\n",
       " '73m2',\n",
       " '80',\n",
       " '8694',\n",
       " '8700',\n",
       " '90',\n",
       " '99',\n",
       " 'abil',\n",
       " 'ability',\n",
       " 'abnorm',\n",
       " 'abnormal',\n",
       " 'about',\n",
       " 'abov',\n",
       " 'above',\n",
       " 'absolut',\n",
       " 'absorpt',\n",
       " 'ac',\n",
       " 'accident',\n",
       " 'accord',\n",
       " 'account',\n",
       " 'accumul',\n",
       " 'ace',\n",
       " 'acei',\n",
       " 'aceis',\n",
       " 'achiev',\n",
       " 'across',\n",
       " 'act',\n",
       " 'action',\n",
       " 'activ',\n",
       " 'activity',\n",
       " 'acut',\n",
       " 'ad',\n",
       " 'added',\n",
       " 'addit',\n",
       " 'addition',\n",
       " 'adequ',\n",
       " 'adjust',\n",
       " 'adjusted',\n",
       " 'administ',\n",
       " 'administr',\n",
       " 'administration',\n",
       " 'adolesc',\n",
       " 'adren',\n",
       " 'adult',\n",
       " 'adults',\n",
       " 'advers',\n",
       " 'ae',\n",
       " 'aes',\n",
       " 'affect',\n",
       " 'affin',\n",
       " 'after',\n",
       " 'afterload',\n",
       " 'ag',\n",
       " 'age',\n",
       " 'agent',\n",
       " 'agranulocytosis',\n",
       " 'albuminuria',\n",
       " 'aldosteron',\n",
       " 'aliskiren',\n",
       " 'all',\n",
       " 'allergy',\n",
       " 'alon',\n",
       " 'alone',\n",
       " 'also',\n",
       " 'alt',\n",
       " 'altern',\n",
       " 'an',\n",
       " 'anaesthesia',\n",
       " 'and',\n",
       " 'anemia',\n",
       " 'angina',\n",
       " 'angioedema',\n",
       " 'angiotensin',\n",
       " 'ani',\n",
       " 'anim',\n",
       " 'animals',\n",
       " 'anoth',\n",
       " 'antagon',\n",
       " 'antagonist',\n",
       " 'anti',\n",
       " 'antihypertens',\n",
       " 'anxiety',\n",
       " 'aortic',\n",
       " 'appear',\n",
       " 'appendag',\n",
       " 'appli',\n",
       " 'appropri',\n",
       " 'appropriate',\n",
       " 'approxim',\n",
       " 'ar',\n",
       " 'arb',\n",
       " 'arbs',\n",
       " 'arrhythmia',\n",
       " 'arteri',\n",
       " 'arthralgia',\n",
       " 'arthritis',\n",
       " 'arthropathy',\n",
       " 'as',\n",
       " 'assess',\n",
       " 'associ',\n",
       " 'ast',\n",
       " 'asthenia',\n",
       " 'at',\n",
       " 'at1',\n",
       " 'at2',\n",
       " 'atacand',\n",
       " 'atrial',\n",
       " 'attain',\n",
       " 'attent',\n",
       " 'auc',\n",
       " 'avail',\n",
       " 'avoid',\n",
       " 'azotemia',\n",
       " 'back',\n",
       " 'barrier',\n",
       " 'base',\n",
       " 'be',\n",
       " 'becaus',\n",
       " 'been',\n",
       " 'benefit',\n",
       " 'beta',\n",
       " 'between',\n",
       " 'bilater',\n",
       " 'bile',\n",
       " 'biliari',\n",
       " 'bind',\n",
       " 'bioactiv',\n",
       " 'bioavail',\n",
       " 'biotransform',\n",
       " 'black',\n",
       " 'blind',\n",
       " 'block',\n",
       " 'blockad',\n",
       " 'blocker',\n",
       " 'blockers',\n",
       " 'blood',\n",
       " 'bodi',\n",
       " 'bond',\n",
       " 'bound',\n",
       " 'bp',\n",
       " 'bradycardia',\n",
       " 'bradykinin',\n",
       " 'brain',\n",
       " 'bun',\n",
       " 'but',\n",
       " 'by',\n",
       " 'calcium',\n",
       " 'can',\n",
       " 'candesartan',\n",
       " 'cannot',\n",
       " 'cardiac',\n",
       " 'cardiovascular',\n",
       " 'case',\n",
       " 'caus',\n",
       " 'caution',\n",
       " 'cell',\n",
       " 'cells',\n",
       " 'central',\n",
       " 'cerebrovascular',\n",
       " 'chang',\n",
       " 'channel',\n",
       " 'charm',\n",
       " 'chemistri',\n",
       " 'chest',\n",
       " 'children',\n",
       " 'cholestasis',\n",
       " 'cilexetil',\n",
       " 'circulatori',\n",
       " 'class',\n",
       " 'clearanc',\n",
       " 'clinic',\n",
       " 'close',\n",
       " 'closely',\n",
       " 'cmax',\n",
       " 'co',\n",
       " 'combin',\n",
       " 'common',\n",
       " 'commonli',\n",
       " 'compar',\n",
       " 'complet',\n",
       " 'compon',\n",
       " 'composit',\n",
       " 'concentr',\n",
       " 'concentrations',\n",
       " 'concern',\n",
       " 'conclusive',\n",
       " 'concomit',\n",
       " 'concomitantli',\n",
       " 'concurr',\n",
       " 'condit',\n",
       " 'condition',\n",
       " 'conditions',\n",
       " 'conduct',\n",
       " 'confusion',\n",
       " 'congest',\n",
       " 'conjunctivitis',\n",
       " 'consciousness',\n",
       " 'consequ',\n",
       " 'consid',\n",
       " 'consider',\n",
       " 'considered',\n",
       " 'consist',\n",
       " 'constant',\n",
       " 'constipation',\n",
       " 'contain',\n",
       " 'container',\n",
       " 'continu',\n",
       " 'contraind',\n",
       " 'contraindications',\n",
       " 'contribut',\n",
       " 'control',\n",
       " 'controlled',\n",
       " 'convert',\n",
       " 'coronari',\n",
       " 'cough',\n",
       " 'could',\n",
       " 'creatinin',\n",
       " 'creatinine',\n",
       " 'cross',\n",
       " 'current',\n",
       " 'cyp',\n",
       " 'cyp1a2',\n",
       " 'cyp2a6',\n",
       " 'cyp2c19',\n",
       " 'cyp2c9',\n",
       " 'cyp2d6',\n",
       " 'cyp2e1',\n",
       " 'cyp3a4',\n",
       " 'cystitis',\n",
       " 'cytochrom',\n",
       " 'dai',\n",
       " 'daili',\n",
       " 'daily',\n",
       " 'dams',\n",
       " 'data',\n",
       " 'date',\n",
       " 'day',\n",
       " 'death',\n",
       " 'decis',\n",
       " 'decreas',\n",
       " 'deethyl',\n",
       " 'defici',\n",
       " 'definit',\n",
       " 'degrad',\n",
       " 'demonstr',\n",
       " 'depend',\n",
       " 'deplet',\n",
       " 'depression',\n",
       " 'detail',\n",
       " 'detected',\n",
       " 'deterior',\n",
       " 'determin',\n",
       " 'determined',\n",
       " 'develop',\n",
       " 'development',\n",
       " 'diabet',\n",
       " 'diabetes',\n",
       " 'diagnosed',\n",
       " 'dialysi',\n",
       " 'dialysis',\n",
       " 'diarrhea',\n",
       " 'did',\n",
       " 'dietari',\n",
       " 'differ',\n",
       " 'digestive',\n",
       " 'digoxin',\n",
       " 'direct',\n",
       " 'directli',\n",
       " 'discontinu',\n",
       " 'disease',\n",
       " 'disord',\n",
       " 'disorder',\n",
       " 'disorders',\n",
       " 'dissoci',\n",
       " 'distribut',\n",
       " 'distribution',\n",
       " 'diuret',\n",
       " 'diuretic',\n",
       " 'diuretics',\n",
       " 'dizzi',\n",
       " 'dizziness',\n",
       " 'dl',\n",
       " 'do',\n",
       " 'doe',\n",
       " 'dosag',\n",
       " 'dose',\n",
       " 'doses',\n",
       " 'dosing',\n",
       " 'doubl',\n",
       " 'drive',\n",
       " 'drug',\n",
       " 'drugs',\n",
       " 'dry',\n",
       " 'dual',\n",
       " 'due',\n",
       " 'dure',\n",
       " 'dyspepsia',\n",
       " 'dyspnea',\n",
       " 'each',\n",
       " 'eczema',\n",
       " 'edema',\n",
       " 'effect',\n",
       " 'efficaci',\n",
       " 'eject',\n",
       " 'elderli',\n",
       " 'elderly',\n",
       " 'electrolyt',\n",
       " 'elev',\n",
       " 'elevated',\n",
       " 'elevation',\n",
       " 'elimin',\n",
       " 'enrol',\n",
       " 'enzym',\n",
       " 'epidemiolog',\n",
       " 'epistaxis',\n",
       " 'escal',\n",
       " 'especi',\n",
       " 'essenti',\n",
       " 'establish',\n",
       " 'established',\n",
       " 'ester',\n",
       " 'estim',\n",
       " 'evalu',\n",
       " 'event',\n",
       " 'evid',\n",
       " 'exacerb',\n",
       " 'example',\n",
       " 'excess',\n",
       " 'exchang',\n",
       " 'exclud',\n",
       " 'excluded',\n",
       " 'excret',\n",
       " 'exist',\n",
       " 'expect',\n",
       " 'experi',\n",
       " 'experienc',\n",
       " 'experience',\n",
       " 'exposur',\n",
       " 'extens',\n",
       " 'extent',\n",
       " 'external',\n",
       " 'face',\n",
       " 'factors',\n",
       " 'failur',\n",
       " 'failure',\n",
       " 'fall',\n",
       " 'fece',\n",
       " 'feces',\n",
       " 'fetal',\n",
       " 'fetotox',\n",
       " 'fetu',\n",
       " 'fever',\n",
       " 'fibrillation',\n",
       " 'find',\n",
       " 'first',\n",
       " 'flushing',\n",
       " 'fold',\n",
       " 'follow',\n",
       " 'food',\n",
       " 'for',\n",
       " 'forms',\n",
       " 'formul',\n",
       " 'found',\n",
       " 'fraction',\n",
       " 'frequenc',\n",
       " 'frequent',\n",
       " 'from',\n",
       " 'function',\n",
       " 'further',\n",
       " 'galactos',\n",
       " 'gastroenteritis',\n",
       " 'gastrointestin',\n",
       " 'gastrointestinal',\n",
       " 'gender',\n",
       " 'gener',\n",
       " 'geriatr',\n",
       " 'geriatrics',\n",
       " 'gestat',\n",
       " 'gfr',\n",
       " 'given',\n",
       " 'gland',\n",
       " 'glucose',\n",
       " 'go',\n",
       " 'granulocytopenia',\n",
       " 'greater',\n",
       " 'ground',\n",
       " 'group',\n",
       " 'ha',\n",
       " 'had',\n",
       " 'half',\n",
       " 'have',\n",
       " 'headache',\n",
       " 'health',\n",
       " 'healthi',\n",
       " 'hearing',\n",
       " 'heart',\n",
       " 'hematocrit',\n",
       " 'hematolog',\n",
       " 'hematologic',\n",
       " 'hematuria',\n",
       " 'hemodialysis',\n",
       " 'hemoglobin',\n",
       " 'hepat',\n",
       " 'hereditari',\n",
       " 'higher',\n",
       " 'highli',\n",
       " 'histori',\n",
       " 'homeostasi',\n",
       " 'hormon',\n",
       " 'hour',\n",
       " 'hours',\n",
       " 'howev',\n",
       " 'however',\n",
       " 'human',\n",
       " 'humans',\n",
       " 'hydrolysi',\n",
       " 'hydronephrosi',\n",
       " 'hyperglycemia',\n",
       " 'hyperkalaemia',\n",
       " 'hyperkalemia',\n",
       " 'hypersensit',\n",
       " 'hypertens',\n",
       " 'hypertension',\n",
       " 'hypertonia',\n",
       " 'hypertriglyceridemia',\n",
       " 'hyperuricemia',\n",
       " 'hypoesthesia',\n",
       " 'hyponatremia',\n",
       " 'hypotens',\n",
       " 'hypotension',\n",
       " 'identifi',\n",
       " 'identifieddiffer',\n",
       " 'if',\n",
       " 'ii',\n",
       " 'iii',\n",
       " 'immediately',\n",
       " 'immunologic',\n",
       " 'impair',\n",
       " 'impairment',\n",
       " 'import',\n",
       " 'importance',\n",
       " 'impotence',\n",
       " 'in',\n",
       " 'inact',\n",
       " 'incid',\n",
       " 'includ',\n",
       " 'increas',\n",
       " 'increased',\n",
       " 'independ',\n",
       " 'indic',\n",
       " 'individu',\n",
       " 'individuals',\n",
       " 'induc',\n",
       " 'infant',\n",
       " 'infarct',\n",
       " 'infarction',\n",
       " 'infect',\n",
       " 'infection',\n",
       " 'infestations',\n",
       " 'inform',\n",
       " 'infrequ',\n",
       " 'infus',\n",
       " 'ingestion',\n",
       " 'ingredi',\n",
       " 'inhibit',\n",
       " 'inhibitor',\n",
       " 'initi',\n",
       " 'institut',\n",
       " 'insufficiency',\n",
       " 'interact',\n",
       " 'interactions',\n",
       " 'intervals',\n",
       " 'into',\n",
       " 'intolerance',\n",
       " 'intravascular',\n",
       " 'intraven',\n",
       " 'investigations',\n",
       " 'involv',\n",
       " 'ion',\n",
       " 'is',\n",
       " 'ischem',\n",
       " 'ischemia',\n",
       " 'isoenzym',\n",
       " 'isoton',\n",
       " 'it',\n",
       " 'iv',\n",
       " 'juvenil',\n",
       " 'kg',\n",
       " 'kidney',\n",
       " 'kininas',\n",
       " 'known',\n",
       " 'label',\n",
       " 'laboratori',\n",
       " 'lactas',\n",
       " 'lactat',\n",
       " 'lapp',\n",
       " 'laryngitis',\n",
       " 'late',\n",
       " 'leg',\n",
       " 'less',\n",
       " 'leukopenia',\n",
       " 'level',\n",
       " 'lif',\n",
       " 'like',\n",
       " 'likelihood',\n",
       " 'limit',\n",
       " 'linear',\n",
       " 'lip',\n",
       " 'list',\n",
       " 'listing',\n",
       " 'littl',\n",
       " 'liver',\n",
       " 'loss',\n",
       " 'lower',\n",
       " 'lowest',\n",
       " 'lymphat',\n",
       " 'machin',\n",
       " 'machines',\n",
       " 'made',\n",
       " 'mai',\n",
       " 'mainli',\n",
       " 'make',\n",
       " 'malabsoprtion',\n",
       " 'malaise',\n",
       " 'mani',\n",
       " 'manifest',\n",
       " 'manner',\n",
       " 'margin',\n",
       " 'market',\n",
       " 'matern',\n",
       " 'maxim',\n",
       " 'maximum',\n",
       " 'mean',\n",
       " 'measur',\n",
       " 'mechanism',\n",
       " 'medic',\n",
       " 'mellitu',\n",
       " 'mellitus',\n",
       " 'menopaus',\n",
       " 'ment',\n",
       " 'meq',\n",
       " 'metabol',\n",
       " 'metabolit',\n",
       " 'metabolite',\n",
       " 'mg',\n",
       " 'mice',\n",
       " 'might',\n",
       " 'mild',\n",
       " 'milk',\n",
       " 'min',\n",
       " 'mineralocorticoid',\n",
       " 'minor',\n",
       " 'miss',\n",
       " 'ml',\n",
       " 'moder',\n",
       " 'modifi',\n",
       " 'monitor',\n",
       " 'monitored',\n",
       " 'monograph',\n",
       " 'monotherapi',\n",
       " 'monotherapy',\n",
       " 'month',\n",
       " 'morbid',\n",
       " 'more',\n",
       " 'most',\n",
       " 'mother',\n",
       " 'mouth',\n",
       " 'much',\n",
       " 'muscl',\n",
       " 'musculoskelet',\n",
       " 'musculoskeletal',\n",
       " 'must',\n",
       " 'myalgia',\n",
       " 'myocardi',\n",
       " 'myopathy',\n",
       " 'myositi',\n",
       " 'necessari',\n",
       " 'necessary',\n",
       " 'need',\n",
       " 'neonat',\n",
       " 'nephropathy',\n",
       " 'nervou',\n",
       " 'neurosis',\n",
       " 'neutropenia',\n",
       " 'never',\n",
       " 'next',\n",
       " 'nitrogen',\n",
       " 'no',\n",
       " 'noael',\n",
       " 'non',\n",
       " 'nor',\n",
       " 'normal',\n",
       " 'normotens',\n",
       " 'not',\n",
       " 'nurs',\n",
       " 'nutrit',\n",
       " 'nutritional',\n",
       " 'nyha',\n",
       " 'observ',\n",
       " 'observed',\n",
       " 'obtain',\n",
       " 'occasionally',\n",
       " 'occur',\n",
       " 'occurr',\n",
       " 'occurs',\n",
       " 'of',\n",
       " 'offspring',\n",
       " 'old',\n",
       " 'older',\n",
       " 'oligohydramnios',\n",
       " 'oliguria',\n",
       " 'on',\n",
       " 'onc',\n",
       " 'once',\n",
       " 'onli',\n",
       " 'open',\n",
       " 'oper',\n",
       " 'or',\n",
       " 'oral',\n",
       " 'orally',\n",
       " 'ossif',\n",
       " 'other',\n",
       " 'otitis',\n",
       " 'out',\n",
       " 'over',\n",
       " 'overal',\n",
       " 'overdosag',\n",
       " 'p450',\n",
       " 'packag',\n",
       " 'paediatr',\n",
       " 'pain',\n",
       " 'palpit',\n",
       " 'palpitation',\n",
       " 'pancreat',\n",
       " 'paramet',\n",
       " 'parasympathet',\n",
       " 'paresthesia',\n",
       " 'particular',\n",
       " 'particularli',\n",
       " 'pass',\n",
       " 'pathwai',\n",
       " 'patient',\n",
       " 'patients',\n",
       " 'peak',\n",
       " 'pectoris',\n",
       " 'pediatr',\n",
       " 'pediatrics',\n",
       " 'penetr',\n",
       " 'perform',\n",
       " 'perfus',\n",
       " 'perfusion',\n",
       " 'period',\n",
       " 'peripher',\n",
       " 'persist',\n",
       " 'pertin',\n",
       " 'pharmacodynam',\n",
       " 'pharmacokinet',\n",
       " 'pharmacolog',\n",
       " 'pharyngolaryng',\n",
       " 'phosphokinase',\n",
       " 'place',\n",
       " 'placebo',\n",
       " 'placent',\n",
       " 'plai',\n",
       " 'plan',\n",
       " 'plasma',\n",
       " 'pneumonia',\n",
       " 'populations',\n",
       " 'possibl',\n",
       " 'possible',\n",
       " 'post',\n",
       " 'potassium',\n",
       " 'potenti',\n",
       " 'practic',\n",
       " 'precautions',\n",
       " 'preclin',\n",
       " 'pregnanc',\n",
       " 'pregnancy',\n",
       " 'pregnant',\n",
       " 'present',\n",
       " 'pressor',\n",
       " 'pressur',\n",
       " 'pressure',\n",
       " 'presyncop',\n",
       " 'primari',\n",
       " 'prior',\n",
       " 'problem',\n",
       " 'procedur',\n",
       " 'prodrug',\n",
       " 'product',\n",
       " 'profil',\n",
       " 'progress',\n",
       " 'pronounc',\n",
       " 'properti',\n",
       " 'protein',\n",
       " 'pruritus',\n",
       " 'psychiatr',\n",
       " 'psychiatric',\n",
       " 'pulmonari',\n",
       " 'raa',\n",
       " 'raas',\n",
       " 'rabbit',\n",
       " 'radioact',\n",
       " 'rang',\n",
       " 'rapidli',\n",
       " 'rare',\n",
       " 'rarely',\n",
       " 'ras',\n",
       " 'rash',\n",
       " 'rat',\n",
       " 'rate',\n",
       " 'rats',\n",
       " 'reabsorpt',\n",
       " 'reach',\n",
       " 'reaction',\n",
       " 'receiv',\n",
       " 'recent',\n",
       " 'receptor',\n",
       " 'recommend',\n",
       " 'recommended',\n",
       " 'recov',\n",
       " 'recoveri',\n",
       " 'red',\n",
       " 'reduc',\n",
       " 'reduct',\n",
       " 'reduction',\n",
       " 'reflect',\n",
       " 'reflex',\n",
       " 'regard',\n",
       " 'regardless',\n",
       " 'regular',\n",
       " 'regulation',\n",
       " 'rel',\n",
       " 'relat',\n",
       " 'relationship',\n",
       " 'relev',\n",
       " 'rememb',\n",
       " 'remembers',\n",
       " 'remov',\n",
       " 'renal',\n",
       " 'renin',\n",
       " 'repeat',\n",
       " 'repeated',\n",
       " 'replet',\n",
       " 'report',\n",
       " 'reproductive',\n",
       " 'requir',\n",
       " 'required',\n",
       " 'resist',\n",
       " 'respectively',\n",
       " 'respiratori',\n",
       " 'respiratory',\n",
       " 'respons',\n",
       " 'response',\n",
       " 'restriction',\n",
       " 'result',\n",
       " 'retardation',\n",
       " 'revers',\n",
       " 'rhabdomyolysi',\n",
       " 'risk',\n",
       " 'role',\n",
       " 'rule',\n",
       " 'safeti',\n",
       " 'salin',\n",
       " 'salt',\n",
       " 'same',\n",
       " 'schedule',\n",
       " 'second',\n",
       " 'secret',\n",
       " 'section',\n",
       " 'see',\n",
       " 'seem',\n",
       " 'seen',\n",
       " 'select',\n",
       " 'sensit',\n",
       " 'seriou',\n",
       " 'serum',\n",
       " 'sever',\n",
       " 'sex',\n",
       " 'should',\n",
       " 'show',\n",
       " 'sign',\n",
       " 'signific',\n",
       " 'similar',\n",
       " 'sinc',\n",
       " 'singl',\n",
       " 'sinu',\n",
       " 'sinus',\n",
       " 'site',\n",
       " 'skelet',\n",
       " 'skin',\n",
       " 'skull',\n",
       " 'slow',\n",
       " 'small',\n",
       " 'smooth',\n",
       " 'sodium',\n",
       " 'solitari',\n",
       " 'solution',\n",
       " 'some',\n",
       " 'somnol',\n",
       " 'soon',\n",
       " 'spar',\n",
       " 'special',\n",
       " 'specialist',\n",
       " 'specif',\n",
       " 'spironolactone',\n",
       " 'standard',\n",
       " 'start',\n",
       " 'started',\n",
       " 'state',\n",
       " 'statu',\n",
       " 'stenosi',\n",
       " 'stenosis',\n",
       " 'stimul',\n",
       " 'stimulation',\n",
       " 'stop',\n",
       " 'stroke',\n",
       " 'strong',\n",
       " 'studi',\n",
       " 'studied',\n",
       " 'studies',\n",
       " 'study',\n",
       " 'subject',\n",
       " 'subjects',\n",
       " 'substitut',\n",
       " 'such',\n",
       " 'sudden',\n",
       " 'sufficient',\n",
       " 'supervis',\n",
       " 'supervision',\n",
       " 'supin',\n",
       " 'support',\n",
       " 'surgeri',\n",
       " 'surviv',\n",
       " 'survival',\n",
       " 'suscept',\n",
       " 'sweating',\n",
       " 'swell',\n",
       " 'sympathomimet',\n",
       " 'symptomat',\n",
       " 'symptoms',\n",
       " 'syncop',\n",
       " 'syncope',\n",
       " 'synthesis',\n",
       " 'system',\n",
       " 'tablet',\n",
       " 'tachycardia',\n",
       " 'take',\n",
       " 'taken',\n",
       " 'target',\n",
       " 'tendon',\n",
       " 'teratogen',\n",
       " 'test',\n",
       " 'tests',\n",
       " 'than',\n",
       " 'that',\n",
       " 'the',\n",
       " 'thei',\n",
       " 'their',\n",
       " 'then',\n",
       " 'theoret',\n",
       " 'therapi',\n",
       " 'therapy',\n",
       " 'there',\n",
       " 'thereafter',\n",
       " 'therefor',\n",
       " 'therefore',\n",
       " 'these',\n",
       " 'thi',\n",
       " 'thiazid',\n",
       " 'third',\n",
       " 'those',\n",
       " 'thrombocytopenia',\n",
       " 'thrombophlebitis',\n",
       " 'through',\n",
       " 'thu',\n",
       " 'tight',\n",
       " 'time',\n",
       " 'tinnitus',\n",
       " 'tissues',\n",
       " 'to',\n",
       " 'toler',\n",
       " 'tongue',\n",
       " 'toothach',\n",
       " 'total',\n",
       " 'toward',\n",
       " 'toxic',\n",
       " 'tract',\n",
       " 'transfus',\n",
       " 'transplant',\n",
       " 'treat',\n",
       " 'treatment',\n",
       " 'trial',\n",
       " 'trials',\n",
       " 'trimest',\n",
       " 'tripl',\n",
       " 'type',\n",
       " 'unchang',\n",
       " 'under',\n",
       " 'undergo',\n",
       " 'underli',\n",
       " 'uneventful',\n",
       " 'unilater',\n",
       " 'unknown',\n",
       " 'unlik',\n",
       " 'up',\n",
       " 'upon',\n",
       " 'upper',\n",
       " 'urea',\n",
       " 'urin',\n",
       " 'urinary',\n",
       " 'urine',\n",
       " 'urogenit',\n",
       " 'urticari',\n",
       " 'urticaria',\n",
       " 'us',\n",
       " 'usual',\n",
       " 'utero',\n",
       " 'vagal',\n",
       " 'valvular',\n",
       " 'vascular',\n",
       " 'vasoact',\n",
       " 'vasoconstriction',\n",
       " 'vasoconstrictor',\n",
       " 'vasodil',\n",
       " 'vehicl',\n",
       " 'veri',\n",
       " 'vertigo',\n",
       " 'via',\n",
       " 'visceral',\n",
       " 'vision',\n",
       " 'vital',\n",
       " 'vitro',\n",
       " 'vivo',\n",
       " 'volum',\n",
       " 'volume',\n",
       " 'vomiting',\n",
       " 'wa',\n",
       " 'warn',\n",
       " 'weakness',\n",
       " 'weari',\n",
       " 'week',\n",
       " 'weeks',\n",
       " 'weigh',\n",
       " 'weight',\n",
       " 'weights',\n",
       " 'well',\n",
       " 'were',\n",
       " 'when',\n",
       " 'whenev',\n",
       " 'whether',\n",
       " 'which',\n",
       " 'white',\n",
       " 'who',\n",
       " 'whole',\n",
       " 'whom',\n",
       " 'whose',\n",
       " 'with',\n",
       " 'withdraw',\n",
       " 'within',\n",
       " 'without',\n",
       " 'women',\n",
       " 'worldwid',\n",
       " 'worsen',\n",
       " 'would',\n",
       " 'year',\n",
       " ...]"
      ]
     },
     "execution_count": 225,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tfidf.get_feature_names()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 226,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1002"
      ]
     },
     "execution_count": 226,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(ml_vec[5])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 227,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "numpy.ndarray"
      ]
     },
     "execution_count": 227,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(ml_vec[2])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 250,
   "metadata": {},
   "outputs": [],
   "source": [
    "Settings = {\n",
    "   \"settings\":{\n",
    "      \"number_of_shards\":1,\n",
    "      \"number_of_replicas\":0\n",
    "   },\n",
    "   \"mappings\":{\n",
    "       \"dynamic\": \"true\",\n",
    "        \"_source\": {\n",
    "        \"enabled\": \"true\"\n",
    "        },\n",
    "       \"properties\":{\n",
    "            \"answer\": {\n",
    "            \"type\": \"text\"\n",
    "            },\n",
    "          \"ml_vector\":{\n",
    "         \"type\":\"dense_vector\",\n",
    "         \"dims\":1002\n",
    "      } \n",
    "    }\n",
    "   }\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 251,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "python client created\n"
     ]
    }
   ],
   "source": [
    "ENDPOINT = \"http://localhost:9200/\"\n",
    "es = Elasticsearch(timeout=600,hosts=ENDPOINT)\n",
    "print(\"python client created\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 267,
   "metadata": {},
   "outputs": [],
   "source": [
    "#creating the database\n",
    "IndexName = 'tfdddidibnmjjkngss'\n",
    "my = es.indices.create(index=IndexName, ignore=[400,404], body=Settings)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 268,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'acknowledged': True,\n",
       " 'shards_acknowledged': True,\n",
       " 'index': 'tfdddidibnmjjkngss'}"
      ]
     },
     "execution_count": 268,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "my"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 269,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['filename', 'country', 'Product name', 'Refined Product Name',\n",
       "       'para_text', 'Possible Questions', 'Comment'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 269,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 270,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'ATACAND (candesartan cilexetil) is indicated for: \\n\\n•\\tHypertension\\no\\tThe treatment of mild to moderate essential hypertension.\\no\\tATACAND may be used alone or concomitantly with thiazide diuretics.\\no\\tThe safety and efficacy of concurrent use with calcium channel blockers have not been established.\\n•\\tHeart Failure\\no\\tThe treatment of NYHA Class II and III heart failure with ejection fraction\\n≤ 40% in addition to standard therapy, with or without an ACE inhibitor. ',\n",
       "  'Possible Questions': 'What is ATACAND used for\\nWhat is ATACAND used for in Canada\\nHow can ATACAND be used\\nHow can ATACAND be used in Canada\\nCan ATACAND be used with calcium channel blockers\\nCan ATACAND be used with calcium channel blockers in Canada\\nCan ATACAND (candesartan cilexetil) be indicated for heartfailure',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Geriatrics (> 65 years of age) : No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. ',\n",
       "  'Possible Questions': 'What is the efficacy of ATACAND in elderly population\\nWhat is the efficacy of ATACAND in elderly population in Canada\\nWhat is the efficacy of ATACAND in Geriatrics (> 65 years of age) ',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Pediatrics (6 to 17 years of age): \\n•\\tHypertension\\nATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see CLINICAL TRIALS).\\n•\\tHeart Failure\\nThe safety and efficacy of ATACAND in the treatment of heart failure has not been established in children and adolescents <18 years. ',\n",
       "  'Possible Questions': 'What is ATACAND used for in children\\nWhat is ATACAND used for in children in canada\\nCan ATACAND be used to treat heart failure in children\\nCan ATACAND be used to treat heart failure in children in canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'ATACAND (candesartan cilexetil) is contraindicated in: \\n\\n•\\tPatients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.\\n\\n•\\tChildren aged <1 year.\\n•\\tPregnant women (see WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women).\\n\\n•\\tNursing women (see WARNINGS AND PRECAUTIONS, Special Populations, Nursing Women).\\n\\n•\\tCombination with aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR < 60 mL/min/1.73m2) (see WARNINGS and PRECAUTIONS, Dual Blockade of the Renin\\n\\n•\\t-Angiotensin System (RAS) and Renal, and DRUG INTERACTIONS, Dual Blockade of the Renin- Angiotensin-System (RAS) with ARBs, ACEIs or aliskiren-containing drugs).\\n\\n•\\tPatients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsoprtion. ',\n",
       "  'Possible Questions': 'Who is ATACAND conracindicated in\\nWho is ATACAND conracindicated in canada\\nWhat are the contraindications of ATACAND ind canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'There is evidence that co-administration of angiotensin receptor antagonists (ARBs), such as ATACAND, or of angiotensin converting enzyme inhibitors (ACEIs) with aliskiren increases the risk of hypotension, syncope, stroke, hyperkalemia and deterioration of renal function, including renal failure, in patients with diabetes mellitus (type 1 or type 2) and/or moderate to severe renal impairment (GFR < 60 mL/min/1.73m2). Therefore, the use of ATACAND in combination with aliskiren-containing drugs is contraindicated in these patients (see CONTRAINDICATIONS). ',\n",
       "  'Possible Questions': 'Can ATACAND be co-administered with aliskiren\\nCan ATACAND be co-administered with aliskiren in Canada\\nIs there any evidence that co-administration of angiotensin receptor antagonists (ARBs), such as ATACAND ?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Avoid the concomitant use of ACE inhibitors and ARBs in patients with diabetic nephropathy. ',\n",
       "  'Possible Questions': 'Can ATACAND be used in diabetic patients\\nCan ATACAND be used in diabetic patients in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'If dual blockade therapy is considered necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ',\n",
       "  'Possible Questions': 'Can dual blocade therapy be used with ATACAND\\nCan dual blocade therapy be used with ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Occasionally, symptomatic hypotension has occurred after administration of candesartan cilexetil. It is more likely to occur in patients who are volume-depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting, or undergoing surgery with anaesthesia. In these patients, because of the potential fall in blood pressure (BP), therapy should be started under close medical supervision. Similar considerations apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in myocardial infarction or cerebrovascular accident. ',\n",
       "  'Possible Questions': 'What happens when ATACAND is administered\\nWhat happens when ATACAND is administered in Canada\\nIn which patients  symptomatic hypotension may occur after administration of candesartan cilexetil\\nIn which patients  symptomatic hypotension may occur after administration of candesartan cilexetil in canada?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Heart Failure : Patients with heart failure given candesartan cilexetil commonly have some reduction in BP. Caution should be observed when initiating therapy.',\n",
       "  'Possible Questions': 'What happens when ATACAND is administered in heart failure patients\\nWhat happens when ATACAND is administered in heart failure patients in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Triple combination of Atacand with an ACE-inhibitor and a mineralocorticoid receptor antagonist used in heart failure is also not recommended. Use of these combinations should be under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ',\n",
       "  'Possible Questions': 'Can ATACAND be used as triple combination therapy in heart patients\\nCan ATACAND be used as combination therapy in heart patients in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Valvular Stenosis \\nThere is concern on theoretical grounds that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction. ',\n",
       "  'Possible Questions': 'Is ATACAND safe to use in patients with vuvlular stenosis\\nIs ATACAND safe to use in patients with vuvlular stenosis in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Heart Failure : In heart failure patients treated with ATACAND, hyperkalemia may occur. During treatment with ATACAND in patients with heart failure, periodic monitoring of serum potassium is recommended, especially when taken concomitantly with ACE inhibitors and potassium-sparing diuretics such as spironolactone. ',\n",
       "  'Possible Questions': 'What happens when ATACAND is administered to patients with heart failure\\nWhat happens when ATACAND is administered to patients with heart failure in Canada\\nCan ATACAND be used to treat Heart failure\\nCan ATACAND be used to treat Heart failure in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The effect of ATACAND on the ability to drive and use machines has not been studied, but based on its pharmacodynamic properties ATACAND is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment. ',\n",
       "  'Possible Questions': 'How does ATACAND affect ability to drive and operate machinery.\\nHow does ATACAND affect ability to drive and operate machinery in Canada\\nCan a patient drive or operate machinery while taking ATACAND\\nCan a patient drive or operate machinery while taking ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': ' As a consequence of inhibiting the renin-angiotensin-aldosterone system (RAAS), changes in renal function have been seen in susceptible individuals. In patients whose renal function may depend on the activity of the RAAS, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death. In susceptible patients, concomitant diuretic use may further increase risk. ',\n",
       "  'Possible Questions': 'How does ATACAND affect patients with renal impairment\\nHow does ATACAND affect patients with renal impairment in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The use of ARBs, including ATACAND, or ACEIs with aliskiren-containing drugs is contraindicated in patients with moderate to severe renal impairment (GFR <60 mL/min/1.73m2) (see CONTRAINDICATIONS and DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACEIs, or aliskiren-containing drugs). ',\n",
       "  'Possible Questions': 'Can ATACAND be used in patients with severe renal impairment\\nCan ATACAND be used in patients with severe renal impairment in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Use of ATACAND should include appropriate assessment of renal function. ',\n",
       "  'Possible Questions': 'Is renal assesment necessary while using ATACAND\\nIs renal assesment necessary while using ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Heart Failure : In heart failure patients, increases in serum creatinine may occur. Dosage reduction, and/or discontinuation of the diuretic, and/or ATACAND, and/or volume repletion may be required. Monitoring of serum creatinine is recommended during dose escalation and periodically thereafter. ',\n",
       "  'Possible Questions': 'How does ATACAND affect heart failure patients\\nHow does ATACAND affect heart failure patients in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'There is limited experience regarding the administration of ATACAND in adult patients with renal transplant. ',\n",
       "  'Possible Questions': 'Can ATACAND be administered in adult patients with renal transplant\\nCan ATACAND be administered in adult patients with renal transplant in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'ATACAND is contraindicated during pregnancy (see CONTRAINDICATIONS). Drugs that act directly on the RAAS can cause fetal and neonatal morbidity and death when administered to pregnant women. When pregnancy is detected, ATACAND should be discontinued as soon as possible.',\n",
       "  'Possible Questions': 'Can ATACAND be used during pregnancy \\nCan ATACAND be used during pregnancy in Canada\\nHow does ATACAND affect pregnancy\\nHow does ATACAND affect pregnancy in Canada\\nCan pregnant women take ATACAND\\nWhen ATACAND should be discontinued as soon as possible.\\nCan pregnant women take ATACAND in Canada\\nIs it advisable to use ATACAND during pregnanacy\\nIs it advisable to use ATACAND during pregnanacy in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Epidemiological evidence regarding the risk of teratogenicity following exposure to ACEIs during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Given the current evidence available on the risk with ARBs, similar risks may exist for this class of drugs. Patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ARBs should be stopped immediately, and, if appropriate, alternative therapy should be started.',\n",
       "  'Possible Questions': 'What are the risks associated with use of ATACAND during pregnancy\\nWhat are the risks associated with use of ATACAND during pregnancy in Canada\\nWhat if pregnancy is diagnosed during candesartan treatment?\\nWhat if pregnancy is diagnosed during candesartan treatment in canada?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The use of ARBs during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). ',\n",
       "  'Possible Questions': 'How does ATACAND affect the foetus\\nHow does ATACAND affect the foetus in Canada\\nWhat are the lists of  human fetotoxicity which observed  on the use of ARBs like candesartan during the second and third trimesters of pregnancy?\\nWhat are the lists of  human fetotoxicity which observed  on the use of ARBs like candesartan during the second and third trimesters of pregnancy in canada?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Animal data : Oral doses ≥ 10 mg candesartan cilexetil/kg/day administered to pregnant rats during late gestation and continued through lactation were associated with reduced survival and an increased incidence of hydronephrosis in the offspring. Candesartan cilexetil given to pregnant rabbits at an oral dose of 3 mg/kg/day caused maternal toxicity (decreased body weight and death) but, in surviving dams, had no adverse effects on fetal survival, fetal weight, or external, visceral, or skeletal development. No maternal toxicity or adverse effects on fetal development were observed when oral doses ≤1000 mg candesartan cilexetil/kg/day were administered to pregnant mice. ',\n",
       "  'Possible Questions': 'what is the dose of atacand administered to pregnant rats during late gestation\\nwhat is the dose of atacand administered to pregnant rats during late gestation in canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'it is not known whether candesartan is excreted in human milk, but significant levels have been found in the milk of lactating rats. Because many drugs are excreted in human milk, and because of their potential for adversely affecting the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. ',\n",
       "  'Possible Questions': 'Can breastfeeding mothers use ATACAND\\nCan breastfeeding mothers use ATACAND in Canada\\nShould ATACAND be used while breastfeeding\\nShould ATACAND be used while breastfeeding in Canada\\nDoes candesartan is excreted in human milk\\nIn which  lactating animal significant levels of candesartan have been found in the milk ?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'In utero exposure : Infants with a history of in utero exposure to ARBs should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function; however, limited experience with those procedures has not been associated with significant clinical benefit. Candesartan cilexetil is not removed from plasma by dialysis. ',\n",
       "  'Possible Questions': 'How does ATACAND affect infants who have undergone in utero exposure \\nHow does ATACAND affect infants who have undergone in utero exposure in Canada\\nCan Candesartan cilexetil be removed from plasma by dialysis.\\nCan Candesartan cilexetil be removed from plasma by dialysis in canada?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Animal data-Heart development : In preclinical studies in normotensive neonatal and juvenile rats, candesartan caused a reduction in relative and absolute heart weights. As in adult animals, these effects were considered to result from the pharmacological action of candesartan. At the lowest dose of 10 mg/kg, exposure to candesartan was 7-54x those found in children aged 6 to <17 years who received 16 mg of candesartan cilexetil. Since a NOAEL (no observed adverse effect level) could not be established in these studies, the safety margin for the effects on heart weight could not be determined. The clinical relevance of this finding is unknown. ',\n",
       "  'Possible Questions': 'How does ATACAND affect heart weight in animals\\nHow does ATACAND affect heart weight in animals in Canada\\nWhy  the safety margin for the effects on heart weight could not be determined in preclinical candesartan studies in normotensive neonatal and juvenile rats\\nWhy  the safety margin for the effects on heart weight could not be determined in preclinical candesartan studies in normotensive neonatal and juvenile rats in canada?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Black pediatric patients:  The antihypertensive effect of candesartan is less pronounced in Black patients compared with non-Black patients. ',\n",
       "  'Possible Questions': 'Is candesartan effective in treating Black patients\\nIs candesartan effective in treating Black patients in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Volume-depleted patients : For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), ATACAND treatment should be initiated under close medical supervision and a lower starting dose should be considered (see DOSAGE AND ADMINISTRATION, Pediatrics).',\n",
       "  'Possible Questions': 'Can ATACAND be used in volume - depleted patients\\nCan ATACAND be used in volume - depleted patients in Canada\\nIn which Volume-depleted patients atacand can be used?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Renal impairment : ATACAND has not been studied in children aged 6 to 17 years with renal impairment (see DOSAGE AND ADMINISTRATION, Pediatrics).',\n",
       "  'Possible Questions': 'Can ATACAND be used in children with renal impairment\\nCan ATACAND be used in children with renal impairment in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'There is no experience regarding the administration of ATACAND in children aged 6 to <17 years with a renal transplant. ',\n",
       "  'Possible Questions': 'Can ATACAND be used in children who underwent a renal transplant\\nCan ATACAND be used in children who underwent a renal transplant in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Hepatic impairment : There are no data on the effects of ATACAND in pediatric patients with hepatic impairment. \\n',\n",
       "  'Possible Questions': 'Can ATACAND be used in children with hepatic impairment\\nCan ATACAND be used in children with hepatic impairment in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Type 1 diabetes : There is no experience regarding the administration of ATACAND in children aged 6 to <17 years with type 1 diabetes. ',\n",
       "  'Possible Questions': 'Can ATACAND be used in children with type 1 diabetes.\\nCan ATACAND be used in children with type 1 diabetes in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'No overall differences in safety or effectiveness were observed between subjects >65 years of age and younger subjects. In addition, other reported clinical experience has not identifieddifferences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.',\n",
       "  'Possible Questions': 'Is ATACAND safe to use in pediatric and elderly population\\nIs ATACAND safe to use in pediatric and elderly population in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Potentially serious adverse reactions reported rarely with candesartan cilexetil in controlled clinical trials were syncope and hypotension. ',\n",
       "  'Possible Questions': 'What are the potentially serious adverse reactions reported with ATACAND\\nWhat are the potentially serious adverse reactions reported with ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The adverse reaction profile of ATACAND as a treatment for hypertension in pediatric patients appeared similar to that seen in adults. However, the frequency of all adverse events (AEs) seemed higher.',\n",
       "  'Possible Questions': 'What are the adverse reactions seen in pediatric patients taking ATACAND\\nWhat are the adverse reactions seen in pediatric patients taking ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking ATACAND for 4 weeks and 1 year, respectively. ',\n",
       "  'Possible Questions': 'What are the adverse reactions seen in pediatric patients taking ATACAND\\nWhat are the adverse reactions seen in pediatric patients taking ATACAND in Canada\\nHow much percentage of Sinus arrhythmia was observed in pediatric patients ',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Severe adverse reactions most commonly seen in adult heart failure patients taking candesartan cilexetil in controlled clinical trials were hypotension, hyperkalemia and renal impairment. ',\n",
       "  'Possible Questions': 'What are the adverse reactions seen in heart failure patients taking ATACAND\\nWhat are the adverse reactions seen in pediatric patients taking ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Clinical Trial Adverse Drug Reactions \\nBecause clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug.  Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates .',\n",
       "  'Possible Questions': 'How are clinicical trials of ATACAND useful\\nHow are clinicical trials of ATACAND useful in Canada\\nWhy adverse reaction rates observed in the clinical trials of Candesartan may not reflect the rates observed in practice ?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'ATACAND (candesartan cilexetil) was evaluated for safety in >8700 patients treated for hypertension, including 677 treated for ≥6 months and 626 for ≥1 year. Of these, 8694 were treated with candesartan cilexetil monotherapy in controlled clinical trials.',\n",
       "  'Possible Questions': 'How was ATACAND evealuated in clinical trials\\nHow was ATACAND evealuated in clinical trials in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'In placebo-controlled clinical trials, discontinuation due to AEs occurred in 2.9% and 2.7% of patients treated with ATACAND monotherapy and placebo, respectively.',\n",
       "  'Possible Questions': 'What was the dicontinuation criteria in clinical trials of ATACAND\\nWhat was the dicontinuation criteria in clinical trials of ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'In the double blind, placebo-controlled trials, the overall incidence of AEs showed no association with dose, age or gender. In these trials, the following AEs reported with ATACAND occurred in ≥ 1% of patients, regardless of drug relationship: ',\n",
       "  'Possible Questions': 'What was the incidence of AEs in placebo controlled trials of ATACAND\\nWhat was the incidence of AEs in placebo controlled trials of ATACAND in ATACAND',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Clinical trials in which doses ≤32 mg were administered did not result in a significant increase in any of the AEs listed above. ',\n",
       "  'Possible Questions': 'Did doses lesser than 32mg affect the clinical trials of ATACAND\\nDid doses lesser than 32mg affect the clinical trials of ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'ATACAND was evaluated for safety in 240 hypertensive pediatric patients aged 6 to 17 years during a 4-week placebo-controlled clinical trial and in 235 pediatric patients in the 1-year open-label extension study. A total of 213 pediatric patients from the placebo-controlled trial enrolled in the open-label study. There were 178 patients who were treated for ≥1 year.',\n",
       "  'Possible Questions': 'How was the safety of ATACAND evaluated in children\\nHow was the safety of ATACAND evaluated in children in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The adverse reaction profile of ATACAND in pediatric patients appeared similar to that seen adults. However, the frequency of all AEs seemed higher.',\n",
       "  'Possible Questions': 'How is the adverse reaction profile of ATACAND in pediatric patients \\nHow is the adverse reaction profile of ATACAND in pediatric patients in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'In the placebo-controlled clinical trial, the most common AEs (≥3% of patients) were cough, dizziness, headache, pharyngolaryngeal pain and upper respiratory tract infection. Dizziness was the most common drug-related AE.',\n",
       "  'Possible Questions': 'What were the most common Aes observed in ATACAND placebo cinical trials\\nWhat were the most common Aes observed in ATACAND placebo cinical trials in  Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'In the open-label extension study, 3 out of 240 pediatric patients aged 6 to 17 years experienced worsening renal disease. The association between candesartan and the exacerbation of the underlying condition could not be excluded',\n",
       "  'Possible Questions': 'Does ATACAND worsen renal disease in children\\nDoes ATACAND worsen renal disease in children in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking ATACAND for 4 weeks and 1 year, respectively. ',\n",
       "  'Possible Questions': 'What are the adverse reactions seen in pediatric patients taking ATACAND\\nWhat are the adverse reactions seen in pediatric patients taking ATACAND in Canada\\nHow much percentage of Sinus arrhythmia was observed in pediatric patients ',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The AE profile of ATACAND in adult heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. In the CHARM-Alternative and CHARM-Added studies comparing ATACAND in total daily doses ≤32 mg once daily to placebo, 23.2 % of ATACAND and 18.4% of placebo patients discontinued the treatment due to AEs.',\n",
       "  'Possible Questions': 'Does ATACAND cause Aes in Heart failure patients\\nDoes ATACAND cause Aes in Heart failure patients in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'In these trials, the following AEs reported with ATACAND occurred in ≥ 1% of patients and with higher frequency than placebo, regardless of drug relationship. ',\n",
       "  'Possible Questions': 'What was the incidence of AEs in placebo controlled trials of ATACAND\\nWhat was the incidence of AEs in placebo controlled trials of ATACAND in ATACAND',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Less Common Clinical Trial Adverse Drug Reactions (< 1%) \\n\\nHypertension ',\n",
       "  'Possible Questions': 'What is the less  Common Clinical Trial Adverse Drug Reactions found during ATACAND treatment',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The following AEs were reported at an incidence of < 1% in controlled clinical trials (in >1 patient, with higher frequency than placebo): \\n\\nBody as a Whole:  allergy, asthenia, pain, syncope. \\nCardiovascular:  angina pectoris, circulatory failure, flushing, hypotension, myocardial infarction, peripheral ischemia, thrombophlebitis. \\nCentral and Peripheral Nervous System:  hypertonia, hypoesthesia, paresthesia, vertigo.  \\nGastrointestinal:  constipation, dry mouth, dyspepsia, toothache .\\nHearing:  tinnitus. \\nMetabolic and Nutritional:  diabetes mellitus, hyperkalemia, hyponatremia.  \\nMusculoskeletal:  arthritis, arthropathy, myalgia, myopathy, skeletal pain, tendon disorder.  \\nBlood:  anemia, epistaxis. \\nPsychiatric:  depression, impotence, neurosis.  \\nReproductive:  menopausal symptoms. \\nResistance Mechanism:  otitis.  \\nRespiratory:  laryngitis. \\nSkin:  eczema, pruritus, rash, skin disorder, sweating, (rarely) urticaria.  \\nUrinary:  abnormal urine, cystitis. \\nVision:  conjunctivitis. ',\n",
       "  'Possible Questions': 'What are the list of  AEs  which were reported at an incidence of < 1% in controlled clinical trials (in >1 patient, with higher frequency than placebo) during ATACAND treatment?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'AEs reported at a rate >1% but at about the same or greater incidence in patients receiving placebo, in studies using daily doses >16 mg: albuminuria, arthralgia, chest pain and sinusitis',\n",
       "  'Possible Questions': 'What are adverse events which were reporetd in the  studies using daily doses >16 mg of ATACAND?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Other AEs reported at an incidence of ≥0.5% from >3200 patients treated worldwide include anxiety, dyspnea, fever, gastroenteritis, hematuria, hyperglycemia, hypertriglyceridemia, hyperuricemia, increased creatinine phosphokinase, palpitation, somnolence and tachycardia. ',\n",
       "  'Possible Questions': 'What are the Other Aes of ATACAND reported at an incidence of ≥0.5% from >3200 patients treated worldwide include ?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The following listed AEs occurred in <1% of patients treated with ATACAND but in ≥2 patients and with more frequent occurrence in the ATACAND group than in the placebo group (CHARM-Alternative and CHARM-Added). \\nSkin and Appendages Disorders:  angioedema, pruritus, rash.  \\nLiver and Biliary System Disorders:  hepatic function abnormal. \\nWhite Cell and Resistance Disorders:  granulocytopenia, leukopenia. ',\n",
       "  'Possible Questions': 'What are the lists of AEs that occurred in <1% of patients treated with ATACAND but in ≥2 patients and with more frequent occurrence in the ATACAND group than in the placebo group ?',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Abnormal Hematologic and Clinical Chemistry Findings  Laboratory Test Findings \\nHypertension \\n\\nIn controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of ATACAND. ',\n",
       "  'Possible Questions': 'Does ATACAND cause changes in laboratory parameters\\nDoes ATACAND cause changes in laboratory parameters in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Liver Function Tests:  In controlled clinical trials, elevations of AST and ALT (> 3x the upper limit of normal) occurred in 0.3% and 0.5%, respectively, of patients treated with ATACAND monotherapy compared to 0.2% and 0.4%, respectively, of patients receiving placebo. ',\n",
       "  'Possible Questions': 'How is liver function affected with use of ATACAND\\nHow is liver function affected with use of ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Serum Potassium:  A small increase (mean increase of 0.1 mEq/L) was observed in hypertensive patients treated with ATACAND alone but was rarely of clinical importance. ',\n",
       "  'Possible Questions': 'How is serum potassium levels affected with use of ATACAND\\nHow is serum potassium levels affected with use of ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Creatinine, Blood Urea Nitrogen, and Sodium:  Infrequent minor increases in blood urea nitrogen (BUN) and serum creatinine as well as decreases in sodium were observed. ',\n",
       "  'Possible Questions': 'How does ATACAND affect creatinie, blood urea nitrogen and sodium levels\\nHow does ATACAND affect creatinie, blood urea nitrogen and sodium levels in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Hemoglobin and Hematocrit:  Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.2 g/dL and 0.5 volume %, respectively) were observed in patients treated with ATACAND alone but were rarely of clinical importance. Anemia, leukopenia and thrombocytopenia were associated with withdrawal of 1 patient each from clinical trials. ',\n",
       "  'Possible Questions': 'How does ATACAND affect Hemoglobin and Hematocrit levels\\nHow does ATACAND affect Hemoglobin and Hematocrit levels in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Hyperuricemia:  Hyperuricemia was rarely found (0.6% of patients treated with ATACAND and 0.5% of patients treated with placebo). ',\n",
       "  'Possible Questions': 'Does ATACAND cause Hyperuricemia\\nDoes ATACAND cause Hyperuricemia in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Heart Failure \\n\\nIncreases in serum creatinine, potassium and urea, and decreases in hemoglobin and hematocrit were observed. ',\n",
       "  'Possible Questions': 'How does ATACAND affect heart failure patients\\nHow does ATACAND affect heart failure patients in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Post-Market Adverse Drug Reactions \\nIn post-marketing experience, the following have been reported in patients treated with ATACAND: \\n\\nBlood and lymphatic disorders:  thrombocytopenia \\n\\nCardiac disorders:  atrial fibrillation, bradycardia, cardiac failure, palpitations \\n\\nDigestive:  abnormal hepatic function and hepatitis \\n\\nGastrointestinal disorders:  pancreatitis \\n\\nGeneral disorders and administration site conditions:  chest pain, malaise, sudden death \\n\\nHematologic:  agranulocytosis, leukopenia and neutropenia \\n\\nImmunologic:  angioedema, involving swelling of the face, lips and/or tongue, hypersensitivity \\n\\nInfections and infestations:  pneumonia \\n\\nInvestigations:  blood creatinine increased, fall \\n\\nMetabolic and Nutritional Disorders:  hyperkalemia and hyponatremia  \\nMusculoskeletal System:  muscle pain, muscle weakness, myositis and rhabdomyolysis  \\nNervous system disorders:  cerebrovascular accident, loss of consciousness, presyncope  \\nPsychiatric disorders:  confusional state \\nRespiratory System Disorders:  cough, pulmonary edema \\n\\nSkin and Appendages Disorders:  pruritus, rash and urticarial \\n\\nUrogenital System:  renal impairment, including renal failure in elderly susceptible patients (see WARNINGS AND PRECAUTIONS, Renal, Renal Impairment for definition of susceptible patients) ',\n",
       "  'Possible Questions': 'What are the Post-Market Adverse Drug Reactions  of ATACAND',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'In vitro studies indicate that cytochrome P450 isoenzyme CYP 2C9 is involved in the biotransformation of candesartan to its inactive metabolite. Based on in vitro data, no interaction would be expected to occur in vivo with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4.\\nInteraction studies have only been performed in adults. \\n',\n",
       "  'Possible Questions': 'How does ATACAND interact invivo with other drugs\\nHow does ATACAND interact invivo with other drugs in Canada\\nIs ATACAND interaction studied in all populations\\nIs ATACAND interaction studied in all populations in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'ATACAND may be taken with or without food ',\n",
       "  'Possible Questions': 'How should ATACAND be taken\\nHow should ATACAND be taken in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The dosage of ATACAND (candesartan cilexetil) must be individualized .',\n",
       "  'Possible Questions': 'What is the average dose of ATACAND\\nWhat is the average dose of ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Recommended Dose and Dosage Adjustment \\n\\nATACAND should be taken once daily, at approximately the same time each day, with or without food. ',\n",
       "  'Possible Questions': 'How many times should ATACAND be taken per day\\nHow many times should ATACAND be taken per day in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Hypertension \\n\\nAdults \\n\\nInitiation of therapy requires consideration of recent antihypertensive treatment, the extent of BP elevation, salt restriction, and other pertinent clinical factors. The dosage of other antihypertensive agents used with ATACAND may need to be adjusted. BP response is dose related over the range of 4 - 32 mg.',\n",
       "  'Possible Questions': 'Can ATACAND be used with antihypertensive drugs\\nCan ATACAND be used with antihypertensive drugs in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The recommended initial dose of ATACAND is 16 mg, once daily when used as monotherapy. Total daily doses of ATACAND should range from 8- 32 mg. Doses >32 mg do not appear to have a greater effect on BP reduction, and there is relatively little experience with such doses. Most of the antihypertensive effect is present within 2 weeks and the maximal BP reduction is generally obtained within 4 weeks. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function) consideration should be given to administration of a lower dose. If BP is not controlled by ATACAND alone, a thiazide diuretic may be added (See DRUG INTERACTIONS, Drug-Drug Interactions, Diuretics). ',\n",
       "  'Possible Questions': 'What is the average dose of ATACAND\\nWhat is the average dose of ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Concomitant Diuretic Therapy \\nIn patients receiving diuretics, ATACAND therapy should be initiated with caution, since these patients may be volume-depleted and thus more likely to experience hypotension following initiation of additional antihypertensive therapy.',\n",
       "  'Possible Questions': 'Can ATACAND be used in patients using diuretics\\nCan ATACAND be used in patients using diuretics in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': \"Whenever possible, all diuretics should be discontinued 2-3 days prior to the administration of ATACAND, to reduce the likelihood of hypotension (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension).  If this is not possible because of the patient's condition, ATACAND should be administered with caution and BP monitored closely. Thereafter, the dosage should be adjusted according to the individual response of the patient. \",\n",
       "  'Possible Questions': 'What happens when ATACAND is administered in patients taking diuretics\\nWhat happens when ATACAND is administered in patients taking diuretics in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Hepatic Impairment \\nMild to moderate hepatic impairment:  No dosage adjustment is necessary. ',\n",
       "  'Possible Questions': 'Is dose adjustment necessary for ATACAND in patients with mild to moderate hepatic impairment\\nIs dose adjustment necessary for ATACAND in patients with mild to moderate hepatic impairment in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Severe hepatic impairment and/or cholestasis:  There is only limited experience. In patients with severely impaired hepatic function, a lower initial dose of 4 mg should be considered. ',\n",
       "  'Possible Questions': 'Is dose adjustment necessary for ATACAND in patients with severe hepatic impairment/ cholestasis\\nIs dose adjustment necessary for ATACAND in patients with severe hepatic impairment/ cholestasis in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Renal Impairment \\nMild renal impairment:  No dosage adjustment is necessary ',\n",
       "  'Possible Questions': 'Is dose adjustment necessary for ATACAND in patients with mild renal impairment\\nIs dose adjustment necessary for ATACAND in patients with mild renal impairment in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Moderate or severe renal impairment or patients undergoing dialysis:  A lower initial dose of 4 mg should be considered. ',\n",
       "  'Possible Questions': 'Is dose adjustment necessary for ATACAND in patients with moderate or severe renal impairment\\nIs dose adjustment necessary for ATACAND in patients with moderate or severe renal impairment in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Geriatrics (> 65 years of age) \\nNo dosage adjustment is necessary for elderly patients. As greater sensitivity of some older patients cannot be ruled out, appropriate caution is recommended (see WARNINGS AND PRECAUTIONS, Geriatrics). ',\n",
       "  'Possible Questions': 'Is dose adjustment necessary for ATACAND in elderly patients\\nIs dose adjustment necessary for ATACAND in elderly patients in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Paediatrics\\n•\\tPatients weighing <50 kg:  The recommended starting dose is 4 mg once daily.\\n\\nIn some patients whose BP is not adequately controlled, the dose can be increased to 8 mg once daily.\\nThe maximum dose is 8 mg once daily ',\n",
       "  'Possible Questions': 'What is the recommended dose of ATACAND in patients lesser than 50kg\\nWhat is the recommended dose of ATACAND in patients lesser than 50kg in Canada\\nWhat is the recommended dose of ATACAND in patients whose BP is not controlled\\nWhat is the recommended dose of ATACAND in patients whose BP is not controlled in Canada\\n',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': '•\\tPatients weighing ≥ 50 kg:  The recommended starting dose is 8 mg once daily.\\n\\nIn some patients whose BP is not adequately controlled, the dose can be increased to 16 mg once daily.\\nThe maximum dose is 16 mg once daily.\\n\\nThe dose should be adjusted according to BP response.\\n\\nMost of the antihypertensive effect is attained within 4 weeks. ',\n",
       "  'Possible Questions': 'What is the recommended dose of ATACAND in patients greater than 50kg\\nWhat is the recommended dose of ATACAND in patients greater than 50kg in Canada\\nWhat is the recommended dose of ATACAND in patients whose BP is not controlled\\nWhat is the recommended dose of ATACAND in patients whose BP is not controlled in Canada\\nShould ATACAND dosage be adjusted in BP patients\\nShould ATACAND dosage be adjusted in BP patients in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Doses >32 mg have not been studied in pediatric patients.',\n",
       "  'Possible Questions': 'What doses of ATACAND is studied in children\\nWhat doses of ATACAND is studied in children in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), ATACAND treatment should be initiated under close medical supervision and a lower starting dose than the general starting dose above should be considered (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics). ',\n",
       "  'Possible Questions': 'Can ATACAND be used in cildren with possible intravascular volume depletion\\nCan ATACAND be used in cildren with possible intravascular volume depletion in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The usual recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily which is achieved by doubling the dose at approximately 2 week intervals, as tolerated by the patient. ATACAND can be administered with other heart failure treatments including ACEIs, beta-blockers, diuretics, digoxin, and/or spironolactone. ',\n",
       "  'Possible Questions': 'What is the usual recommended dose of ATACAND for treating heart failure\\nWhat is the usual recommended dose of ATACAND for treating heart failure in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'No initial dose adjustment is necessary for elderly patients or in patients with renal or hepatic impairment. ',\n",
       "  'Possible Questions': 'Is dose adjustment necessary for elderly patients or in patients with renal or hepatic impairment taking ATACAND\\nIs dose adjustment necessary for elderly patients or in patients with renal or hepatic impairment taking ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'The safety and efficacy of ATACAND in the treatment of heart failure have not been established in children and adolescents <18 years of age. ',\n",
       "  'Possible Questions': 'Is the safety and efficacy of ATACAND in the treatment of heart failure have not been established in children and adolescents <18 years of age.',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'If a patient misses a dose of ATACAND and remembers within 12 hours, the patient should take the dose as soon as possible and then go back to the regular schedule. If it is more than 12 hours after the patient remembers, they should not take the missed dose; the next dose should be taken on time.',\n",
       "  'Possible Questions': 'What should a patient do if they miss a dose of ATACAND\\nWhat should a patient do if they miss a dose of ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'A double dose of ATACAND should never be taken to make up for a missed dose. ',\n",
       "  'Possible Questions': 'Can a double dose of ATACAND be taken in case of a missed dose\\nCan a double dose of ATACAND be taken in case of a missed dose in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Limited data are available in regard to overdosage in humans. The most likely manifestations of overdosage would be hypotension, dizziness and tachycardia; bradycardia could occur from reflex parasympathetic (vagal) stimulation. In case reports detailing overdosage [≤672 mg ATACAND (candesartan cilexetil)] in adults, patient recovery was uneventful.',\n",
       "  'Possible Questions': 'How is overdosage of ATACAND manifested in humans\\nHow is overdosage of ATACAND manifested in humans in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'If symptomatic hypotension should occur, supportive treatment should be instituted and vital signs monitored. The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be increased by infusion of, for example, isotonic saline solution. Sympathomimetic drugs may also be administered if the above-mentioned measures are not sufficient. Candesartan cilexetil is not removed from the plasma by hemodialysis. ',\n",
       "  'Possible Questions': 'What should be done in case of symptomatic hypertension while taking ATACAND\\nWhat should be done in case of symptomatic hypertension while taking ATACAND in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'ATACAND (candesartan cilexetil) antagonizes angiotensin II by blocking the angiotensin type one (AT1) receptor. Angiotensin II is the primary vasoactive hormone of RAAS with effects that include vasoconstriction, stimulation of aldosterone secretion and renal reabsorption of sodium.',\n",
       "  'Possible Questions': 'How does ATACAND work\\nHow does ATACAND work in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Candesartan cilexetil, a prodrug, is rapidly converted to the active drug, candesartan, during absorption from the gastrointestinal tract.',\n",
       "  'Possible Questions': 'How is ATACAND converted in the gastrointestinal tract\\nHow is ATACAND converted in the gastrointestinal tract in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Candesartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis. There is also an AT2 receptor found in many tissues, but it plays no known role in cardiovascular homeostasis to date. Candesartan has a much greater affinity (> 10,000 fold) for the AT1 receptor than for the AT2 receptor. The strong bond between candesartan and the AT1 receptor is a result of tight binding to and slow dissociation from the receptor.',\n",
       "  'Possible Questions': 'How does ATACAND affect the angiotensin system\\nHow does ATACAND affect the angiotensin system in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Candesartan does not inhibit ACE, also known as kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin, nor does it bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. ',\n",
       "  'Possible Questions': 'How does ATACAND affect ACE inhibitors\\nHow does ATACAND affect ACE inhibitors in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Candesartan inhibits the pressor effects of angiotensin II infusion in a dose dependent manner. After 1 week of once-daily dosing of 8 mg candesartan cilexetil, the pressor effect was inhibited by approximately 90% at peak (4-8 hours after dosing) with approximately 50% inhibition persisting at 24 hours.',\n",
       "  'Possible Questions': 'How does ATACAND affect the pressor effect of of angiotensin II infusion \\nHow does ATACAND affect the pressor effect of of angiotensin II infusion in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Plasma concentrations of angiotensin I, angiotensin II, and plasma renin activity, increased in a dose-dependent manner after single and repeated administration of candesartan cilexetil to adult healthy subjects, hypertensive and heart failure patients. A decrease in the plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was administered to hypertensive patients. ',\n",
       "  'Possible Questions': 'How does ATACAND affect Angiotensin I, Angiotensin II and plasma renin activity\\nHow does ATACAND affect Angiotensin I, Angiotensin II and plasma renin activity in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Absorption : Following oral administration of candesartan cilexetil as a tablet, the absolute bioavailability of candesartan is estimated to be approximately 15%. After tablet ingestion, the peak serum concentration (Cmax) is reached after 3-4 hours. Food does not affect the bioavailability of candesartan after candesartan cilexetil administration .',\n",
       "  'Possible Questions': 'How is ATACAND absorbed in the system\\nHow is ATACAND absorbed in the system in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Distribution:  The volume of distribution of candesartan is 0.13 L/kg. Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells. The protein binding is constant at candesartan plasma concentrations well above the range achieved with recommended doses. In rats, it has been demonstrated that candesartan does cross the blood- brain barrier. It has also been demonstrated in rats that candesartan passes across the placental barrier and is distributed in the fetus .',\n",
       "  'Possible Questions': 'How is ATACAND distributed in the system\\nHow is ATACAND distributed in the system in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Metabolism : Candesartan cilexetil is rapidly and completely bioactivated to candesartan by ester hydrolysis during absorption from the gastrointestinal tract. It undergoes minor hepatic metabolism by O-deethylation to an inactive metabolite. In vitro studies indicate that cytochrome P450 isoenzyme CYP 2C9 is involved in the biotransformation of candesartan to its inactive metabolite. Based on in vitro data, no interaction would be expected to occur in vivo with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4. ',\n",
       "  'Possible Questions': 'How is ATACAND metabolised in the system\\nHow is ATACAND metabolised in the system in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Excretion : Total plasma clearance of candesartan is 0.37 mL/min/kg, with a renal clearance of 0.19 mL/min/kg. Candesartan is mainly excreted unchanged in urine and feces (via bile). When candesartan cilexetil is administered orally, about 26% of the dose is excreted as candesartan in urine. Following an oral dose of 14C-labeled candesartan cilexetil, approximately 33% of radioactivity is recovered in urine and approximately 67% in feces. Following an intravenous (iv) dose of 14C-labeled candesartan, approximately 59% of radioactivity is recovered in urine and approximately 36% in feces. Biliary excretion contributes to the elimination of candesartan. The elimination half-life of candesartan is approximately 9 hours. After single and repeated administration, the pharmacokinetics of candesartan are linear for oral doses ≤32 mg. Candesartan and its inactive metabolite do not accumulate in serum upon repeated once-daily dosing. ',\n",
       "  'Possible Questions': 'How is ATACAND excreted from the system\\nHow is ATACAND excreted from the system in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Geriatrics : The plasma concentration of candesartan was higher in the elderly (≥ 65 years old) (Cmax was approximately 50% higher, and AUC was approximately 80% higher) compared to younger subjects administered the same dose. The pharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite did not accumulate in the serum of these subjects upon repeated, once-daily administration. ',\n",
       "  'Possible Questions': 'How is the plasma concentration of ATACAND affected in the elderly\\nHow is the plasma concentration of ATACAND affected in the elderly in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Pediatrics (6 to 17 years of age) : Pediatric (6 to 17 years of age) hypertensive patients that received a 16 mg dose of candesartan cilexetil had exposure similar to adults given the same dose. The pharmacokinetics (Cmax and AUC) were not modified by age, sex or body weight. From the dose-ranging studies of candesartan cilexetil, there was a dose related increase in plasma candesartan concentrations.',\n",
       "  'Possible Questions': 'How is the plasma concentration of ATACAND affected in pediatric hypertensive patients \\nHow is the plasma concentration of ATACAND affected in pediatric hypertensive patients in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'ATACAND pharmacokinetics have not been determined in children and adolescent (6 to 17 years of age) with renal insufficiency. ',\n",
       "  'Possible Questions': 'How is ATACAND pharmacokinetics affected in children with renal insufficiency\\nHow is ATACAND pharmacokinetics affected in children with renal insufficiency in Canada',\n",
       "  'Comment': nan},\n",
       " {'filename': 'Candesartan_PM_Reviewed.docx',\n",
       "  'country': 'Canada',\n",
       "  'Product name': 'Candesartan cilexetil',\n",
       "  'Refined Product Name': 'Atacand (Candesartan Cilexetil)',\n",
       "  'para_text': 'Gender : No gender-related differences in the pharmacokinetics of candesartan have been observed.',\n",
       "  'Possible Questions': 'Is the pharmacokinetics of ATACAND affected by gender\\nIs the pharmacokinetics of ATACAND affected by gender in Canada',\n",
       "  'Comment': nan}]"
      ]
     },
     "execution_count": 270,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df22 = df.to_dict('records')\n",
    "df22"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 271,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "99"
      ]
     },
     "execution_count": 271,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df22)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 272,
   "metadata": {},
   "outputs": [],
   "source": [
    "arr=[]\n",
    "for c, line in enumerate(df22):\n",
    "    arr.append({\"answer\":line.get(\"para_text\",\"\"),\n",
    "    'ml_vector':ml_vec[c]})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 273,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'answer': 'ATACAND (candesartan cilexetil) is indicated for: \\n\\n•\\tHypertension\\no\\tThe treatment of mild to moderate essential hypertension.\\no\\tATACAND may be used alone or concomitantly with thiazide diuretics.\\no\\tThe safety and efficacy of concurrent use with calcium channel blockers have not been established.\\n•\\tHeart Failure\\no\\tThe treatment of NYHA Class II and III heart failure with ejection fraction\\n≤ 40% in addition to standard therapy, with or without an ACE inhibitor. ',\n",
       " 'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])}"
      ]
     },
     "execution_count": 273,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "arr[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 274,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'answer': 'ATACAND (candesartan cilexetil) is indicated for: \\n\\n•\\tHypertension\\no\\tThe treatment of mild to moderate essential hypertension.\\no\\tATACAND may be used alone or concomitantly with thiazide diuretics.\\no\\tThe safety and efficacy of concurrent use with calcium channel blockers have not been established.\\n•\\tHeart Failure\\no\\tThe treatment of NYHA Class II and III heart failure with ejection fraction\\n≤ 40% in addition to standard therapy, with or without an ACE inhibitor. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Geriatrics (> 65 years of age) : No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. ',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.10373278, 0.        ,\n",
       "         0.32895898])},\n",
       " {'answer': 'Pediatrics (6 to 17 years of age): \\n•\\tHypertension\\nATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see CLINICAL TRIALS).\\n•\\tHeart Failure\\nThe safety and efficacy of ATACAND in the treatment of heart failure has not been established in children and adolescents <18 years. ',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.20894465, 0.19286821,\n",
       "         0.        ])},\n",
       " {'answer': 'ATACAND (candesartan cilexetil) is contraindicated in: \\n\\n•\\tPatients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.\\n\\n•\\tChildren aged <1 year.\\n•\\tPregnant women (see WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women).\\n\\n•\\tNursing women (see WARNINGS AND PRECAUTIONS, Special Populations, Nursing Women).\\n\\n•\\tCombination with aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR < 60 mL/min/1.73m2) (see WARNINGS and PRECAUTIONS, Dual Blockade of the Renin\\n\\n•\\t-Angiotensin System (RAS) and Renal, and DRUG INTERACTIONS, Dual Blockade of the Renin- Angiotensin-System (RAS) with ARBs, ACEIs or aliskiren-containing drugs).\\n\\n•\\tPatients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsoprtion. ',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.04708728, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'There is evidence that co-administration of angiotensin receptor antagonists (ARBs), such as ATACAND, or of angiotensin converting enzyme inhibitors (ACEIs) with aliskiren increases the risk of hypotension, syncope, stroke, hyperkalemia and deterioration of renal function, including renal failure, in patients with diabetes mellitus (type 1 or type 2) and/or moderate to severe renal impairment (GFR < 60 mL/min/1.73m2). Therefore, the use of ATACAND in combination with aliskiren-containing drugs is contraindicated in these patients (see CONTRAINDICATIONS). ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Avoid the concomitant use of ACE inhibitors and ARBs in patients with diabetic nephropathy. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'If dual blockade therapy is considered necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Occasionally, symptomatic hypotension has occurred after administration of candesartan cilexetil. It is more likely to occur in patients who are volume-depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting, or undergoing surgery with anaesthesia. In these patients, because of the potential fall in blood pressure (BP), therapy should be started under close medical supervision. Similar considerations apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in myocardial infarction or cerebrovascular accident. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Heart Failure : Patients with heart failure given candesartan cilexetil commonly have some reduction in BP. Caution should be observed when initiating therapy.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Triple combination of Atacand with an ACE-inhibitor and a mineralocorticoid receptor antagonist used in heart failure is also not recommended. Use of these combinations should be under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Valvular Stenosis \\nThere is concern on theoretical grounds that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Heart Failure : In heart failure patients treated with ATACAND, hyperkalemia may occur. During treatment with ATACAND in patients with heart failure, periodic monitoring of serum potassium is recommended, especially when taken concomitantly with ACE inhibitors and potassium-sparing diuretics such as spironolactone. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'The effect of ATACAND on the ability to drive and use machines has not been studied, but based on its pharmacodynamic properties ATACAND is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': ' As a consequence of inhibiting the renin-angiotensin-aldosterone system (RAAS), changes in renal function have been seen in susceptible individuals. In patients whose renal function may depend on the activity of the RAAS, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death. In susceptible patients, concomitant diuretic use may further increase risk. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'The use of ARBs, including ATACAND, or ACEIs with aliskiren-containing drugs is contraindicated in patients with moderate to severe renal impairment (GFR <60 mL/min/1.73m2) (see CONTRAINDICATIONS and DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACEIs, or aliskiren-containing drugs). ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Use of ATACAND should include appropriate assessment of renal function. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Heart Failure : In heart failure patients, increases in serum creatinine may occur. Dosage reduction, and/or discontinuation of the diuretic, and/or ATACAND, and/or volume repletion may be required. Monitoring of serum creatinine is recommended during dose escalation and periodically thereafter. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'There is limited experience regarding the administration of ATACAND in adult patients with renal transplant. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'ATACAND is contraindicated during pregnancy (see CONTRAINDICATIONS). Drugs that act directly on the RAAS can cause fetal and neonatal morbidity and death when administered to pregnant women. When pregnancy is detected, ATACAND should be discontinued as soon as possible.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Epidemiological evidence regarding the risk of teratogenicity following exposure to ACEIs during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Given the current evidence available on the risk with ARBs, similar risks may exist for this class of drugs. Patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ARBs should be stopped immediately, and, if appropriate, alternative therapy should be started.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'The use of ARBs during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Animal data : Oral doses ≥ 10 mg candesartan cilexetil/kg/day administered to pregnant rats during late gestation and continued through lactation were associated with reduced survival and an increased incidence of hydronephrosis in the offspring. Candesartan cilexetil given to pregnant rabbits at an oral dose of 3 mg/kg/day caused maternal toxicity (decreased body weight and death) but, in surviving dams, had no adverse effects on fetal survival, fetal weight, or external, visceral, or skeletal development. No maternal toxicity or adverse effects on fetal development were observed when oral doses ≤1000 mg candesartan cilexetil/kg/day were administered to pregnant mice. ',\n",
       "  'ml_vector': array([0.        , 0.08544033, 0.09947789, ..., 0.        , 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'it is not known whether candesartan is excreted in human milk, but significant levels have been found in the milk of lactating rats. Because many drugs are excreted in human milk, and because of their potential for adversely affecting the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'In utero exposure : Infants with a history of in utero exposure to ARBs should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function; however, limited experience with those procedures has not been associated with significant clinical benefit. Candesartan cilexetil is not removed from plasma by dialysis. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Animal data-Heart development : In preclinical studies in normotensive neonatal and juvenile rats, candesartan caused a reduction in relative and absolute heart weights. As in adult animals, these effects were considered to result from the pharmacological action of candesartan. At the lowest dose of 10 mg/kg, exposure to candesartan was 7-54x those found in children aged 6 to <17 years who received 16 mg of candesartan cilexetil. Since a NOAEL (no observed adverse effect level) could not be established in these studies, the safety margin for the effects on heart weight could not be determined. The clinical relevance of this finding is unknown. ',\n",
       "  'ml_vector': array([0.        , 0.10826114, 0.        , ..., 0.06827738, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'Black pediatric patients:  The antihypertensive effect of candesartan is less pronounced in Black patients compared with non-Black patients. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Volume-depleted patients : For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), ATACAND treatment should be initiated under close medical supervision and a lower starting dose should be considered (see DOSAGE AND ADMINISTRATION, Pediatrics).',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Renal impairment : ATACAND has not been studied in children aged 6 to 17 years with renal impairment (see DOSAGE AND ADMINISTRATION, Pediatrics).',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.19134581, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'There is no experience regarding the administration of ATACAND in children aged 6 to <17 years with a renal transplant. ',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.22926742, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'Hepatic impairment : There are no data on the effects of ATACAND in pediatric patients with hepatic impairment. \\n',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Type 1 diabetes : There is no experience regarding the administration of ATACAND in children aged 6 to <17 years with type 1 diabetes. ',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.18307925, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'No overall differences in safety or effectiveness were observed between subjects >65 years of age and younger subjects. In addition, other reported clinical experience has not identifieddifferences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.10854269, 0.        ,\n",
       "         0.34421225])},\n",
       " {'answer': 'Potentially serious adverse reactions reported rarely with candesartan cilexetil in controlled clinical trials were syncope and hypotension. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'The adverse reaction profile of ATACAND as a treatment for hypertension in pediatric patients appeared similar to that seen in adults. However, the frequency of all adverse events (AEs) seemed higher.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking ATACAND for 4 weeks and 1 year, respectively. ',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.18285937, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'Severe adverse reactions most commonly seen in adult heart failure patients taking candesartan cilexetil in controlled clinical trials were hypotension, hyperkalemia and renal impairment. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Clinical Trial Adverse Drug Reactions \\nBecause clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug.  Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates .',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'ATACAND (candesartan cilexetil) was evaluated for safety in >8700 patients treated for hypertension, including 677 treated for ≥6 months and 626 for ≥1 year. Of these, 8694 were treated with candesartan cilexetil monotherapy in controlled clinical trials.',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.12071917, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'In placebo-controlled clinical trials, discontinuation due to AEs occurred in 2.9% and 2.7% of patients treated with ATACAND monotherapy and placebo, respectively.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'In the double blind, placebo-controlled trials, the overall incidence of AEs showed no association with dose, age or gender. In these trials, the following AEs reported with ATACAND occurred in ≥ 1% of patients, regardless of drug relationship: ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Clinical trials in which doses ≤32 mg were administered did not result in a significant increase in any of the AEs listed above. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'ATACAND was evaluated for safety in 240 hypertensive pediatric patients aged 6 to 17 years during a 4-week placebo-controlled clinical trial and in 235 pediatric patients in the 1-year open-label extension study. A total of 213 pediatric patients from the placebo-controlled trial enrolled in the open-label study. There were 178 patients who were treated for ≥1 year.',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.25778033, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'The adverse reaction profile of ATACAND in pediatric patients appeared similar to that seen adults. However, the frequency of all AEs seemed higher.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'In the placebo-controlled clinical trial, the most common AEs (≥3% of patients) were cough, dizziness, headache, pharyngolaryngeal pain and upper respiratory tract infection. Dizziness was the most common drug-related AE.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'In the open-label extension study, 3 out of 240 pediatric patients aged 6 to 17 years experienced worsening renal disease. The association between candesartan and the exacerbation of the underlying condition could not be excluded',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.12912564, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking ATACAND for 4 weeks and 1 year, respectively. ',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.18285937, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'The AE profile of ATACAND in adult heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. In the CHARM-Alternative and CHARM-Added studies comparing ATACAND in total daily doses ≤32 mg once daily to placebo, 23.2 % of ATACAND and 18.4% of placebo patients discontinued the treatment due to AEs.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'In these trials, the following AEs reported with ATACAND occurred in ≥ 1% of patients and with higher frequency than placebo, regardless of drug relationship. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Less Common Clinical Trial Adverse Drug Reactions (< 1%) \\n\\nHypertension ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'The following AEs were reported at an incidence of < 1% in controlled clinical trials (in >1 patient, with higher frequency than placebo): \\n\\nBody as a Whole:  allergy, asthenia, pain, syncope. \\nCardiovascular:  angina pectoris, circulatory failure, flushing, hypotension, myocardial infarction, peripheral ischemia, thrombophlebitis. \\nCentral and Peripheral Nervous System:  hypertonia, hypoesthesia, paresthesia, vertigo.  \\nGastrointestinal:  constipation, dry mouth, dyspepsia, toothache .\\nHearing:  tinnitus. \\nMetabolic and Nutritional:  diabetes mellitus, hyperkalemia, hyponatremia.  \\nMusculoskeletal:  arthritis, arthropathy, myalgia, myopathy, skeletal pain, tendon disorder.  \\nBlood:  anemia, epistaxis. \\nPsychiatric:  depression, impotence, neurosis.  \\nReproductive:  menopausal symptoms. \\nResistance Mechanism:  otitis.  \\nRespiratory:  laryngitis. \\nSkin:  eczema, pruritus, rash, skin disorder, sweating, (rarely) urticaria.  \\nUrinary:  abnormal urine, cystitis. \\nVision:  conjunctivitis. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'AEs reported at a rate >1% but at about the same or greater incidence in patients receiving placebo, in studies using daily doses >16 mg: albuminuria, arthralgia, chest pain and sinusitis',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Other AEs reported at an incidence of ≥0.5% from >3200 patients treated worldwide include anxiety, dyspnea, fever, gastroenteritis, hematuria, hyperglycemia, hypertriglyceridemia, hyperuricemia, increased creatinine phosphokinase, palpitation, somnolence and tachycardia. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'The following listed AEs occurred in <1% of patients treated with ATACAND but in ≥2 patients and with more frequent occurrence in the ATACAND group than in the placebo group (CHARM-Alternative and CHARM-Added). \\nSkin and Appendages Disorders:  angioedema, pruritus, rash.  \\nLiver and Biliary System Disorders:  hepatic function abnormal. \\nWhite Cell and Resistance Disorders:  granulocytopenia, leukopenia. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Abnormal Hematologic and Clinical Chemistry Findings  Laboratory Test Findings \\nHypertension \\n\\nIn controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of ATACAND. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Liver Function Tests:  In controlled clinical trials, elevations of AST and ALT (> 3x the upper limit of normal) occurred in 0.3% and 0.5%, respectively, of patients treated with ATACAND monotherapy compared to 0.2% and 0.4%, respectively, of patients receiving placebo. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Serum Potassium:  A small increase (mean increase of 0.1 mEq/L) was observed in hypertensive patients treated with ATACAND alone but was rarely of clinical importance. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Creatinine, Blood Urea Nitrogen, and Sodium:  Infrequent minor increases in blood urea nitrogen (BUN) and serum creatinine as well as decreases in sodium were observed. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Hemoglobin and Hematocrit:  Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.2 g/dL and 0.5 volume %, respectively) were observed in patients treated with ATACAND alone but were rarely of clinical importance. Anemia, leukopenia and thrombocytopenia were associated with withdrawal of 1 patient each from clinical trials. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Hyperuricemia:  Hyperuricemia was rarely found (0.6% of patients treated with ATACAND and 0.5% of patients treated with placebo). ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Heart Failure \\n\\nIncreases in serum creatinine, potassium and urea, and decreases in hemoglobin and hematocrit were observed. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Post-Market Adverse Drug Reactions \\nIn post-marketing experience, the following have been reported in patients treated with ATACAND: \\n\\nBlood and lymphatic disorders:  thrombocytopenia \\n\\nCardiac disorders:  atrial fibrillation, bradycardia, cardiac failure, palpitations \\n\\nDigestive:  abnormal hepatic function and hepatitis \\n\\nGastrointestinal disorders:  pancreatitis \\n\\nGeneral disorders and administration site conditions:  chest pain, malaise, sudden death \\n\\nHematologic:  agranulocytosis, leukopenia and neutropenia \\n\\nImmunologic:  angioedema, involving swelling of the face, lips and/or tongue, hypersensitivity \\n\\nInfections and infestations:  pneumonia \\n\\nInvestigations:  blood creatinine increased, fall \\n\\nMetabolic and Nutritional Disorders:  hyperkalemia and hyponatremia  \\nMusculoskeletal System:  muscle pain, muscle weakness, myositis and rhabdomyolysis  \\nNervous system disorders:  cerebrovascular accident, loss of consciousness, presyncope  \\nPsychiatric disorders:  confusional state \\nRespiratory System Disorders:  cough, pulmonary edema \\n\\nSkin and Appendages Disorders:  pruritus, rash and urticarial \\n\\nUrogenital System:  renal impairment, including renal failure in elderly susceptible patients (see WARNINGS AND PRECAUTIONS, Renal, Renal Impairment for definition of susceptible patients) ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'In vitro studies indicate that cytochrome P450 isoenzyme CYP 2C9 is involved in the biotransformation of candesartan to its inactive metabolite. Based on in vitro data, no interaction would be expected to occur in vivo with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4.\\nInteraction studies have only been performed in adults. \\n',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'ATACAND may be taken with or without food ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'The dosage of ATACAND (candesartan cilexetil) must be individualized .',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Recommended Dose and Dosage Adjustment \\n\\nATACAND should be taken once daily, at approximately the same time each day, with or without food. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Hypertension \\n\\nAdults \\n\\nInitiation of therapy requires consideration of recent antihypertensive treatment, the extent of BP elevation, salt restriction, and other pertinent clinical factors. The dosage of other antihypertensive agents used with ATACAND may need to be adjusted. BP response is dose related over the range of 4 - 32 mg.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'The recommended initial dose of ATACAND is 16 mg, once daily when used as monotherapy. Total daily doses of ATACAND should range from 8- 32 mg. Doses >32 mg do not appear to have a greater effect on BP reduction, and there is relatively little experience with such doses. Most of the antihypertensive effect is present within 2 weeks and the maximal BP reduction is generally obtained within 4 weeks. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function) consideration should be given to administration of a lower dose. If BP is not controlled by ATACAND alone, a thiazide diuretic may be added (See DRUG INTERACTIONS, Drug-Drug Interactions, Diuretics). ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Concomitant Diuretic Therapy \\nIn patients receiving diuretics, ATACAND therapy should be initiated with caution, since these patients may be volume-depleted and thus more likely to experience hypotension following initiation of additional antihypertensive therapy.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': \"Whenever possible, all diuretics should be discontinued 2-3 days prior to the administration of ATACAND, to reduce the likelihood of hypotension (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension).  If this is not possible because of the patient's condition, ATACAND should be administered with caution and BP monitored closely. Thereafter, the dosage should be adjusted according to the individual response of the patient. \",\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Hepatic Impairment \\nMild to moderate hepatic impairment:  No dosage adjustment is necessary. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Severe hepatic impairment and/or cholestasis:  There is only limited experience. In patients with severely impaired hepatic function, a lower initial dose of 4 mg should be considered. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Renal Impairment \\nMild renal impairment:  No dosage adjustment is necessary ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Moderate or severe renal impairment or patients undergoing dialysis:  A lower initial dose of 4 mg should be considered. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Geriatrics (> 65 years of age) \\nNo dosage adjustment is necessary for elderly patients. As greater sensitivity of some older patients cannot be ruled out, appropriate caution is recommended (see WARNINGS AND PRECAUTIONS, Geriatrics). ',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.13530067, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'Paediatrics\\n•\\tPatients weighing <50 kg:  The recommended starting dose is 4 mg once daily.\\n\\nIn some patients whose BP is not adequately controlled, the dose can be increased to 8 mg once daily.\\nThe maximum dose is 8 mg once daily ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': '•\\tPatients weighing ≥ 50 kg:  The recommended starting dose is 8 mg once daily.\\n\\nIn some patients whose BP is not adequately controlled, the dose can be increased to 16 mg once daily.\\nThe maximum dose is 16 mg once daily.\\n\\nThe dose should be adjusted according to BP response.\\n\\nMost of the antihypertensive effect is attained within 4 weeks. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Doses >32 mg have not been studied in pediatric patients.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), ATACAND treatment should be initiated under close medical supervision and a lower starting dose than the general starting dose above should be considered (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics). ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'The usual recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily which is achieved by doubling the dose at approximately 2 week intervals, as tolerated by the patient. ATACAND can be administered with other heart failure treatments including ACEIs, beta-blockers, diuretics, digoxin, and/or spironolactone. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'No initial dose adjustment is necessary for elderly patients or in patients with renal or hepatic impairment. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'The safety and efficacy of ATACAND in the treatment of heart failure have not been established in children and adolescents <18 years of age. ',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.18976415, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'If a patient misses a dose of ATACAND and remembers within 12 hours, the patient should take the dose as soon as possible and then go back to the regular schedule. If it is more than 12 hours after the patient remembers, they should not take the missed dose; the next dose should be taken on time.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'A double dose of ATACAND should never be taken to make up for a missed dose. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Limited data are available in regard to overdosage in humans. The most likely manifestations of overdosage would be hypotension, dizziness and tachycardia; bradycardia could occur from reflex parasympathetic (vagal) stimulation. In case reports detailing overdosage [≤672 mg ATACAND (candesartan cilexetil)] in adults, patient recovery was uneventful.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'If symptomatic hypotension should occur, supportive treatment should be instituted and vital signs monitored. The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be increased by infusion of, for example, isotonic saline solution. Sympathomimetic drugs may also be administered if the above-mentioned measures are not sufficient. Candesartan cilexetil is not removed from the plasma by hemodialysis. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'ATACAND (candesartan cilexetil) antagonizes angiotensin II by blocking the angiotensin type one (AT1) receptor. Angiotensin II is the primary vasoactive hormone of RAAS with effects that include vasoconstriction, stimulation of aldosterone secretion and renal reabsorption of sodium.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Candesartan cilexetil, a prodrug, is rapidly converted to the active drug, candesartan, during absorption from the gastrointestinal tract.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Candesartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis. There is also an AT2 receptor found in many tissues, but it plays no known role in cardiovascular homeostasis to date. Candesartan has a much greater affinity (> 10,000 fold) for the AT1 receptor than for the AT2 receptor. The strong bond between candesartan and the AT1 receptor is a result of tight binding to and slow dissociation from the receptor.',\n",
       "  'ml_vector': array([0.09518037, 0.08174924, 0.        , ..., 0.        , 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'Candesartan does not inhibit ACE, also known as kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin, nor does it bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Candesartan inhibits the pressor effects of angiotensin II infusion in a dose dependent manner. After 1 week of once-daily dosing of 8 mg candesartan cilexetil, the pressor effect was inhibited by approximately 90% at peak (4-8 hours after dosing) with approximately 50% inhibition persisting at 24 hours.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Plasma concentrations of angiotensin I, angiotensin II, and plasma renin activity, increased in a dose-dependent manner after single and repeated administration of candesartan cilexetil to adult healthy subjects, hypertensive and heart failure patients. A decrease in the plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was administered to hypertensive patients. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Absorption : Following oral administration of candesartan cilexetil as a tablet, the absolute bioavailability of candesartan is estimated to be approximately 15%. After tablet ingestion, the peak serum concentration (Cmax) is reached after 3-4 hours. Food does not affect the bioavailability of candesartan after candesartan cilexetil administration .',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Distribution:  The volume of distribution of candesartan is 0.13 L/kg. Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells. The protein binding is constant at candesartan plasma concentrations well above the range achieved with recommended doses. In rats, it has been demonstrated that candesartan does cross the blood- brain barrier. It has also been demonstrated in rats that candesartan passes across the placental barrier and is distributed in the fetus .',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Metabolism : Candesartan cilexetil is rapidly and completely bioactivated to candesartan by ester hydrolysis during absorption from the gastrointestinal tract. It undergoes minor hepatic metabolism by O-deethylation to an inactive metabolite. In vitro studies indicate that cytochrome P450 isoenzyme CYP 2C9 is involved in the biotransformation of candesartan to its inactive metabolite. Based on in vitro data, no interaction would be expected to occur in vivo with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Excretion : Total plasma clearance of candesartan is 0.37 mL/min/kg, with a renal clearance of 0.19 mL/min/kg. Candesartan is mainly excreted unchanged in urine and feces (via bile). When candesartan cilexetil is administered orally, about 26% of the dose is excreted as candesartan in urine. Following an oral dose of 14C-labeled candesartan cilexetil, approximately 33% of radioactivity is recovered in urine and approximately 67% in feces. Following an intravenous (iv) dose of 14C-labeled candesartan, approximately 59% of radioactivity is recovered in urine and approximately 36% in feces. Biliary excretion contributes to the elimination of candesartan. The elimination half-life of candesartan is approximately 9 hours. After single and repeated administration, the pharmacokinetics of candesartan are linear for oral doses ≤32 mg. Candesartan and its inactive metabolite do not accumulate in serum upon repeated once-daily dosing. ',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])},\n",
       " {'answer': 'Geriatrics : The plasma concentration of candesartan was higher in the elderly (≥ 65 years old) (Cmax was approximately 50% higher, and AUC was approximately 80% higher) compared to younger subjects administered the same dose. The pharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite did not accumulate in the serum of these subjects upon repeated, once-daily administration. ',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.08461056, 0.        ,\n",
       "         0.13415915])},\n",
       " {'answer': 'Pediatrics (6 to 17 years of age) : Pediatric (6 to 17 years of age) hypertensive patients that received a 16 mg dose of candesartan cilexetil had exposure similar to adults given the same dose. The pharmacokinetics (Cmax and AUC) were not modified by age, sex or body weight. From the dose-ranging studies of candesartan cilexetil, there was a dose related increase in plasma candesartan concentrations.',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.17833874, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'ATACAND pharmacokinetics have not been determined in children and adolescent (6 to 17 years of age) with renal insufficiency. ',\n",
       "  'ml_vector': array([0.        , 0.        , 0.        , ..., 0.20835406, 0.        ,\n",
       "         0.        ])},\n",
       " {'answer': 'Gender : No gender-related differences in the pharmacokinetics of candesartan have been observed.',\n",
       "  'ml_vector': array([0., 0., 0., ..., 0., 0., 0.])}]"
      ]
     },
     "execution_count": 274,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "arr"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 275,
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in range(0,len(arr)):\n",
    "\n",
    "    resp=es.index(index=IndexName,doc_type=\"_doc\",id=i,body=arr[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 276,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'_index': 'tfdddidibnmjjkngss',\n",
       " '_type': '_doc',\n",
       " '_id': '98',\n",
       " '_version': 1,\n",
       " 'result': 'created',\n",
       " '_shards': {'total': 1, 'successful': 1, 'failed': 0},\n",
       " '_seq_no': 98,\n",
       " '_primary_term': 1}"
      ]
     },
     "execution_count": 276,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "resp"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 277,
   "metadata": {},
   "outputs": [],
   "source": [
    "#testing\n",
    "que = \"How does ATACAND affect adults who have undergone in utero exposure\"\n",
    "que_vec= tfidf.transform([que]).toarray()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 278,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[0., 0., 0., ..., 0., 0., 0.]])"
      ]
     },
     "execution_count": 278,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "que_vec"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 279,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1002"
      ]
     },
     "execution_count": 279,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(que_vec[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 280,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "script_query = {\n",
    "\"script_score\": {\n",
    "\"query\": {\"match_all\":{}},\n",
    "\"script\": {\n",
    "\"source\": \"cosineSimilarity(params.query_vector, doc['ml_vector']) \",\n",
    "\"params\": {\"query_vector\":que_vec[0]}\n",
    "}}}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 281,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'took': 13,\n",
       " 'timed_out': False,\n",
       " '_shards': {'total': 1, 'successful': 1, 'skipped': 0, 'failed': 0},\n",
       " 'hits': {'total': {'value': 94, 'relation': 'eq'},\n",
       "  'max_score': 0.16260412,\n",
       "  'hits': [{'_index': 'tfdddidibnmjjkngss',\n",
       "    '_type': '_doc',\n",
       "    '_id': '23',\n",
       "    '_score': 0.16260412,\n",
       "    '_source': {'answer': 'In utero exposure : Infants with a history of in utero exposure to ARBs should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function; however, limited experience with those procedures has not been associated with significant clinical benefit. Candesartan cilexetil is not removed from plasma by dialysis. '}},\n",
       "   {'_index': 'tfdddidibnmjjkngss',\n",
       "    '_type': '_doc',\n",
       "    '_id': '34',\n",
       "    '_score': 0.14736003,\n",
       "    '_source': {'answer': 'Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking ATACAND for 4 weeks and 1 year, respectively. '}},\n",
       "   {'_index': 'tfdddidibnmjjkngss',\n",
       "    '_type': '_doc',\n",
       "    '_id': '45',\n",
       "    '_score': 0.14736003,\n",
       "    '_source': {'answer': 'Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking ATACAND for 4 weeks and 1 year, respectively. '}},\n",
       "   {'_index': 'tfdddidibnmjjkngss',\n",
       "    '_type': '_doc',\n",
       "    '_id': '76',\n",
       "    '_score': 0.1353674,\n",
       "    '_source': {'answer': 'Doses >32 mg have not been studied in pediatric patients.'}},\n",
       "   {'_index': 'tfdddidibnmjjkngss',\n",
       "    '_type': '_doc',\n",
       "    '_id': '42',\n",
       "    '_score': 0.12619655,\n",
       "    '_source': {'answer': 'The adverse reaction profile of ATACAND in pediatric patients appeared similar to that seen adults. However, the frequency of all AEs seemed higher.'}},\n",
       "   {'_index': 'tfdddidibnmjjkngss',\n",
       "    '_type': '_doc',\n",
       "    '_id': '80',\n",
       "    '_score': 0.120871924,\n",
       "    '_source': {'answer': 'The safety and efficacy of ATACAND in the treatment of heart failure have not been established in children and adolescents <18 years of age. '}},\n",
       "   {'_index': 'tfdddidibnmjjkngss',\n",
       "    '_type': '_doc',\n",
       "    '_id': '33',\n",
       "    '_score': 0.11672772,\n",
       "    '_source': {'answer': 'The adverse reaction profile of ATACAND as a treatment for hypertension in pediatric patients appeared similar to that seen in adults. However, the frequency of all adverse events (AEs) seemed higher.'}},\n",
       "   {'_index': 'tfdddidibnmjjkngss',\n",
       "    '_type': '_doc',\n",
       "    '_id': '61',\n",
       "    '_score': 0.10335373,\n",
       "    '_source': {'answer': 'In vitro studies indicate that cytochrome P450 isoenzyme CYP 2C9 is involved in the biotransformation of candesartan to its inactive metabolite. Based on in vitro data, no interaction would be expected to occur in vivo with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4.\\nInteraction studies have only been performed in adults. \\n'}},\n",
       "   {'_index': 'tfdddidibnmjjkngss',\n",
       "    '_type': '_doc',\n",
       "    '_id': '22',\n",
       "    '_score': 0.096450545,\n",
       "    '_source': {'answer': 'it is not known whether candesartan is excreted in human milk, but significant levels have been found in the milk of lactating rats. Because many drugs are excreted in human milk, and because of their potential for adversely affecting the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. '}},\n",
       "   {'_index': 'tfdddidibnmjjkngss',\n",
       "    '_type': '_doc',\n",
       "    '_id': '12',\n",
       "    '_score': 0.09449054,\n",
       "    '_source': {'answer': 'The effect of ATACAND on the ability to drive and use machines has not been studied, but based on its pharmacodynamic properties ATACAND is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment. '}}]}}"
      ]
     },
     "execution_count": 281,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "es.search(index=IndexName,body={\"size\": 10,\"query\": script_query,\"_source\": {\"includes\": [\"answer\"]}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 282,
   "metadata": {},
   "outputs": [],
   "source": [
    "def questions():\n",
    "    count=0\n",
    "    que_arr=[]\n",
    "    for x in df[\"Possible Questions\"]:\n",
    "        sent=x.split(\"\\n\")\n",
    "        for q in sent:\n",
    "            que_arr.append([q,count])\n",
    "        count+=1\n",
    "    return que_arr"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 283,
   "metadata": {},
   "outputs": [],
   "source": [
    "que_arr=questions()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 284,
   "metadata": {},
   "outputs": [],
   "source": [
    "ans=es.search(index=IndexName,body={\"size\": 10,\"query\": script_query,\"_source\": {\"includes\": [\"answer\"]}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 285,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "def rank(ans):\n",
    "    required=ans['hits']\n",
    "    main_arr=required[\"hits\"]\n",
    "    count=1\n",
    "    ids__=dict()\n",
    "    for x in main_arr:\n",
    "        id_no= x[\"_id\"]\n",
    "\n",
    "        score=x[\"_score\"]\n",
    "\n",
    "        answer_=x[\"_source\"][\"answer\"]\n",
    "\n",
    "        ids__[id_no.strip()]=1/count\n",
    "        count+=1\n",
    "    return ids__\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 286,
   "metadata": {},
   "outputs": [],
   "source": [
    "ranker=rank(ans)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 287,
   "metadata": {},
   "outputs": [],
   "source": [
    "ans=es.search(index=IndexName,body={\"size\": 10,\"query\": script_query,\"_source\": {\"includes\": [\"answer\"]}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 301,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "ename": "AttributeError",
     "evalue": "'list' object has no attribute 'lower'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-301-8c7fb13b5cdc>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m      5\u001b[0m     \u001b[0mid_number\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      6\u001b[0m     \u001b[0mquestion\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstem_documents\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mquestion11\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 7\u001b[0;31m     \u001b[0mque_vec\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtfidf\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtransform\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mquestion\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtoarray\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      8\u001b[0m     \u001b[0mans\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mes\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msearch\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mindex\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mIndexName\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mbody\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m{\u001b[0m\u001b[0;34m\"size\"\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;36m10\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\"query\"\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mscript_query\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\"_source\"\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;34m{\u001b[0m\u001b[0;34m\"includes\"\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0;34m\"answer\"\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m}\u001b[0m\u001b[0;34m}\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      9\u001b[0m     \u001b[0mranker\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mrank\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mans\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/biobertnew/lib/python3.6/site-packages/sklearn/feature_extraction/text.py\u001b[0m in \u001b[0;36mtransform\u001b[0;34m(self, raw_documents, copy)\u001b[0m\n\u001b[1;32m   1878\u001b[0m                    \"be removed in 0.24.\")\n\u001b[1;32m   1879\u001b[0m             \u001b[0mwarnings\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mwarn\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmsg\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mFutureWarning\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1880\u001b[0;31m         \u001b[0mX\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msuper\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtransform\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mraw_documents\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1881\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_tfidf\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtransform\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mX\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcopy\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mFalse\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1882\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/biobertnew/lib/python3.6/site-packages/sklearn/feature_extraction/text.py\u001b[0m in \u001b[0;36mtransform\u001b[0;34m(self, raw_documents)\u001b[0m\n\u001b[1;32m   1248\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1249\u001b[0m         \u001b[0;31m# use the same matrix-building strategy as fit_transform\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1250\u001b[0;31m         \u001b[0m_\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mX\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_count_vocab\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mraw_documents\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfixed_vocab\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mTrue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1251\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mbinary\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1252\u001b[0m             \u001b[0mX\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdata\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mfill\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/biobertnew/lib/python3.6/site-packages/sklearn/feature_extraction/text.py\u001b[0m in \u001b[0;36m_count_vocab\u001b[0;34m(self, raw_documents, fixed_vocab)\u001b[0m\n\u001b[1;32m   1108\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mdoc\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mraw_documents\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1109\u001b[0m             \u001b[0mfeature_counter\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m{\u001b[0m\u001b[0;34m}\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1110\u001b[0;31m             \u001b[0;32mfor\u001b[0m \u001b[0mfeature\u001b[0m \u001b[0;32min\u001b[0m \u001b[0manalyze\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdoc\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1111\u001b[0m                 \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1112\u001b[0m                     \u001b[0mfeature_idx\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mvocabulary\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mfeature\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/biobertnew/lib/python3.6/site-packages/sklearn/feature_extraction/text.py\u001b[0m in \u001b[0;36m_analyze\u001b[0;34m(doc, analyzer, tokenizer, ngrams, preprocessor, decoder, stop_words)\u001b[0m\n\u001b[1;32m    102\u001b[0m     \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    103\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mpreprocessor\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 104\u001b[0;31m             \u001b[0mdoc\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mpreprocessor\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdoc\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    105\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mtokenizer\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    106\u001b[0m             \u001b[0mdoc\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtokenizer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdoc\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/biobertnew/lib/python3.6/site-packages/sklearn/feature_extraction/text.py\u001b[0m in \u001b[0;36m_preprocess\u001b[0;34m(doc, accent_function, lower)\u001b[0m\n\u001b[1;32m     67\u001b[0m     \"\"\"\n\u001b[1;32m     68\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mlower\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 69\u001b[0;31m         \u001b[0mdoc\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdoc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlower\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     70\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0maccent_function\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     71\u001b[0m         \u001b[0mdoc\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0maccent_function\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdoc\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mAttributeError\u001b[0m: 'list' object has no attribute 'lower'"
     ]
    }
   ],
   "source": [
    "total=0\n",
    "count=0\n",
    "for x in que_arr:\n",
    "    question11=x[0].strip()\n",
    "    id_number=str(x[1])\n",
    "    question=p.stem_documents(question11)\n",
    "    que_vec=tfidf.transform([question]).toarray()\n",
    "    ans=es.search(index=IndexName,body={\"size\": 10,\"query\": script_query,\"_source\": {\"includes\": [\"answer\"]}})\n",
    "    ranker=rank(ans)\n",
    "    if id_number in ranker:\n",
    "        total+=ranker[id_number]\n",
    "        print(ranker[id_number])\n",
    "    else:\n",
    "        print(0)\n",
    "    count+=1\n",
    "\n",
    "print(\"total is\"+str(total/count))\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 289,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0.1     10\n",
      "0.1     10\n",
      "0.1     10\n",
      "0.1     10\n",
      "0.1     10\n",
      "0.1     10\n",
      "1.0     1\n",
      "1.0     1\n",
      "1.0     1\n",
      "1.0     1\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0.125     8\n",
      "0.125     8\n",
      "0.5     2\n",
      "0.5     2\n",
      "0.5     2\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0.2     5\n",
      "0.2     5\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0.3333333333333333     3\n",
      "0.3333333333333333     3\n",
      "0.3333333333333333     3\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0.1111111111111111     9\n",
      "0.1111111111111111     9\n",
      "0.1111111111111111     9\n",
      "0.1111111111111111     9\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0.25     4\n",
      "0.25     4\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0.16666666666666666     6\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0.14285714285714285     7\n",
      "0.14285714285714285     7\n",
      "0\n",
      "0\n"
     ]
    },
    {
     "ename": "KeyError",
     "evalue": "'98'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyError\u001b[0m                                  Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-289-f06778ee25eb>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     15\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     16\u001b[0m     \u001b[0mtp\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 17\u001b[0;31m \u001b[0;32mif\u001b[0m \u001b[0mranker\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mid_number\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m>\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     18\u001b[0m     \u001b[0mtp\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtp\u001b[0m\u001b[0;34m+\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     19\u001b[0m     \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtp\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mKeyError\u001b[0m: '98'"
     ]
    }
   ],
   "source": [
    "total=0\n",
    "count=0\n",
    "for x in que_arr:\n",
    "    question=x[0].strip()\n",
    "    id_number=str(x[1])\n",
    "    que_vec=tfidf.transform([question]).toarray()\n",
    "    ans=es.search(index=IndexName,body={\"size\": 10,\"query\": script_query,\"_source\": {\"includes\": [\"answer\"]}})\n",
    "    ranker=rank(ans)\n",
    "    if id_number in ranker:\n",
    "        total+=ranker[id_number]\n",
    "        print(str(ranker[id_number]) +\"     \"+ str(int(1/ranker[id_number])))\n",
    "    else:\n",
    "        print(0)\n",
    "    count+=1\n",
    "\n",
    "    tp=0\n",
    "if ranker[id_number]>0:\n",
    "    tp=tp+1\n",
    "    print(tp)\n",
    "mrr=total/count\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 315,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0.12133891213389121\n"
     ]
    }
   ],
   "source": [
    "tp=0\n",
    "count=0\n",
    "fn=0\n",
    "for x in que_arr:\n",
    "    question=x[0].strip()\n",
    "    id_number=str(x[1])\n",
    "    que_vec=tfidf.transform([question]).toarray()\n",
    "    ans=es.search(index=IndexName,body={\"size\": 10,\"query\": script_query,\"_source\": {\"includes\": [\"answer\"]}})\n",
    "    ranker=rank(ans)\n",
    "    if id_number in ranker:\n",
    "        tp+=1\n",
    "    else:\n",
    "        fn+=1\n",
    "    count+=1\n",
    "recall=tp/(tp+fn)\n",
    "print(recall)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 298,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'e'"
      ]
     },
     "execution_count": 298,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question[5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "biobertnew",
   "language": "python",
   "name": "biobertnew"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
